Study of urinary level of kidney injury molecule-1 (KIM-1) in acute kidney injury. by Neethu, Varghese
STUDY OF URINARY LEVEL OF KIDNEY INJURY 
MOLECULE-1 (KIM-1) IN ACUTE KIDNEY INJURY 
 
Dissertation Submittedfor 
M.D DEGREE BRANCH - XIII 
[BIO CHEMISTRY] 
 
DEPARTMENT OF BIOCHEMISTRY 
THANJAVUR MEDICAL COLLEGE, 
THANJAVUR 
 
THE TAMILNADU DR.MGR MEDICAL UNIVERSITY, 
CHENNAI 
APRIL - 2016 
GUIDE CERTFICATE 
 
GUIDE: Prof. Dr. N.SASIVATHANAM M.D., D.G.O., 
    THE PROFESSOR AND HEAD OF THE DEPARTMENT, 
     Department of Biochemistry 
     Thanjavur medical college & Hospital, 
     Thanjavur. 
   
CHIEF CO-ORDINATOR: 
 Prof.  Dr .N.SASIVATHANAM M.D. ,D.G.O., 
 THE  PROFESSOR AND HEAD OF THE DEPARTMENT, 
 Department of Biochemistry, 
 Thanjavur medical college & Hospital, 
 Thanjavur. 
 
 
Remark of the Guide: 
 
The work done by DR. NEETHU VARGHESE on “ STUDY OF 
URINARY LEVEL OF KIDNEY INJURY MOLECULE-1 (KIM-1) IN 
ACUTE KIDNEY INJURY”  is under my supervision and I assure that this 
candidate will abide by the rules of the Ethical Committee. 
 
 
 
 
 GUIDE:                  Prof. Dr .N.SASIVATHANAM M.D. ,D.G.O., 
THE  PROFESSOR AND 
HOD,Department of Biochemistry, 
            Thanjavur medical college & Hospital, 
            Thanjavur 
 
 
 
 
 
  
CERTIFICATE 
 
This is to certify that dissertation titled “STUDY OF URINARY LEVEL 
OF KIDNEY INJURY MOLECULE-1 (KIM-1) IN ACUTE KIDNEY 
INJURY” is a bonafide work done by  Dr.NEETHU VARGHESE under my 
guidance and supervision in the Department of Biochemistry, Thanjavur Medical 
College, Thanjavur during her post graduate course from 2012 to 2015. 
 
   (Dr. M. Singaravelu, M.D., DCH )               (Dr. N.SASIVATHANAM M.D. D.G.O) 
    THE DEAN                                                   Professor and Head of the Department 
Thanjavur Medical College                      Department of Biochemistry 
Thanjavur-4         Thanjavur Medical College 
          Thanjavur-4  
 
  
 DECLARATION 
 
I, Dr.NEETHU VARGHESE hereby solemnly declare that the dissertation 
title “STUDY OF URINARY LEVEL OF KIDNEY INJURY MOLECULE-1 
(KIM-1) IN ACUTE KIDNEY INJURY”  was done by me at Thanjavur  
Medical College and Hospital, Thanjavur under the Supervision and Guidance of 
my Professor and Head of  the Department Dr.N.Sasivathanam, M.D( 
Bio).,DGO.  This dissertation is submitted to The Tamil Nadu Dr. M.G.R Medical 
University, towards partial fulfillment of requirement for the award of M.D. 
Degree (Branch –XIII) in Biochemistry. 
 
    
Place : THANJAVUR 
 
Date :                                                                     (Dr. NEETHU VARGHESE) 
 
 
 
 
 
 
 
 
 
                         ANTI-PLAGIARISM – ORIGINAL REPORT 
 
 
 
 
 
 
 
 
 ACKNOWLEDGEMENT 
 
I am thankful to the Almighty who is the source of every good and perfect gift. 
I am extremely grateful to Dr. M. SINGARAVELU, MD(Ped), DCH ., The 
Dean ,Thanjavur Medical College for permitting me to do this dissertation at 
Thanjavur Medical College Hospital, Thanjavur.  
I am indebted greatly to my Professor and Head of the Department,  
Department of Biochemistry, Dr. N.SASIVATHANAM, M.D(Bio),DGO. who had 
inspired, encouraged and guided me in every step of this study.  
I express my sincere gratitude to Dr. K. NAGARAJAN, HOD and Professor of 
Department of General Medicine and Internal Medicine, for his valuable help. 
I express my heartiest thanks to Dr .S.GANESAN,M.D(Bio)., Associate Professor 
of Biochemistry and Dr.JOSEPHINE LATHA ;M.D(Bio); Associate Professor, 
Department of Biochemistry, Thanjavur Medical College for their help and 
suggestions for performing my study.  
I Sincerely thank my Assistant Professors Dr.R.Rajeswari, M.D(Bio).,DD., 
Dr.M.Ramadevi, M.D(Bio).,D.C.H., and Dr.P.Sunithapriya M.D(Bio)., 
Department of Biochemistry for their support during my study. 
I owe my thanks to my co-post graduates for their support during the study.  
I would like to acknowledge the assistance rendered by Non Medical assistants and 
the Technical staffs who helped me to perform the study.  
I am grateful to all my patients and volunteers who participated in this study. I owe 
my special thanks to my family members for their moral support in conducting the 
study.  
 
 
 
 
 
 
 
 
                                          CONTENTS 
 
S. NO. PARTICULARS PAGE NO. 
1 INTRODUCTION 1 
2 REVIEW OF LITERATURE 4 
3 AIM AND OBJECTIVES 41 
4 MATERIALS AND METHODS 42 
5 RESULTS AND STATISTICS 59 
6 DISCUSSION 69 
7 CONCLUSION 76 
8 LIMITATIONS 77 
 ANNEXURE  
 BIBLIOGRAPHY  
 PROFORMA  
 CONSENT FORM  
 
 
 
                                   
                      ABBREVIATIONS 
 
AKI                                           :  Acute Kidney Injury 
BUN                                          :  Blood Urea Nitrogen 
ARF                                           :   Acute Renal Failure 
CKD                                          :  Chronic Kidney Disease 
KIM-1                                       : Kidney Injury Molecule -1 
TIMS                                         :   T-cell Immunoglobulin Mucin proteins  
ATN                                          :  Acute Tubular Necrosis  
AKIN                                        :  Acute Kidney Injury Network 
ADQI                                        :  Acute Dialysis Quality Initiative 
GFR                                          :  Glomerular Filtration Rate 
RRT                                          :  Renal Replacement Therapy 
KDIGO                                     : Kidney Disease Improving Global Outcome 
NSAIDs                                    : Non-steroidal Anti- Inflammatory Drugs 
MCP-1                                      : Monocyte Chemoattractant Protein-1 
IL-8                                           :  Interleukin-8 
ICAM-1                                    : Intercellular Adhesion Molecule-1 
ATP                                           : Adenosine Triphosphate 
  
 
ET-1                                           : Endothelin-1 
PCT                                           : Proximal Convoluted Tubule 
ADF                                           : Actin Depolymerisation Factor 
TNF-α                                        : Tumor Necrosis Factor- α 
ROS                                           :  Reactive Oxygen Species 
NO                                             : Nitric Oxide 
LPS                                            :  Lipopolysaccharide 
DIC                                            : Disseminated Intravascular Coagulation 
LDL                                           : Low Density Lipoprotein 
ELISA                                        : Enzyme Linked Immuno Sorbent Assay 
 
 
 
 
 
 
 
 
                                      INTRODUCTION  
       
               Acute kidney injury (AKI), otherwise known as acute renal failure, is 
characterized by a sudden impairment of kidney function which results in the retention of 
nitrogenous waste products, during a period that varies between a few hours to several 
weeks.1 
              AKI is a group of heterogenous conditions that are characterized by an increase 
in the Blood Urea Nitrogen (BUN) concentration and/or an increase in the Serum 
Creatinine concentration, often associated with a reduced urine volume.1 
               AKI is a new consensus term encompassing a spectrum of kidney disease of 
acute onset, which may range in severity from asymptomatic changes in the laboratory 
parameters of glomerular filtration rate, to rapidly fatal changes in the regulation of 
effective circulating volume and composition of plasma electrolyte and acid-base 
balance.1 Hence the term AKI has replaced the term acute renal failure (ARF) since AKI 
denotes the entire spectrum of clinical features ranging from mild increase in serum 
creatinine levels to overt renal failure.2  
             There is an enormously growing burden of AKI which is associated with an  
increased risk of mortality among those who are hospitalized, especially in those 
admitted to the Intensive Care Unit.1 The incidence of hospital-acquired AKI has been 
increasing from the past few years which has been validated within a single patient 
population from 1996 through 2003. 
               Despite the advances in dialysis and intensive care, the mortality rates continue 
to be high from 30 to 65%. AKI was not only associated with an increased mortality, but 
also an increase in the hospital stay period and the overall cost.2 The long term 
consequences of AKI include the risk of ending up in CKD stages 4 and 5. 
             The assessment of renal function traditionally involves the measurement of 
serum blood urea nitrogen and serum creatinine which are insensitive and nonspecific, to 
adequately detect renal injury prior to significant loss of renal function.3 And also it is 
important to note that serum blood urea nitrogen and creatinine are not true ‘injury 
markers’, but are primarily markers of ‘functional changes in filtration capacity’. 
                Of late, there is an urgent need of biomarkers for AKI for the timely diagnosis, 
and to predict the severity and outcome of AKI. 
                 
                  Kidney Injury Molecule-1 (KIM-1) is a recently discovered transmembrane 
protein found in the renal tubules, that are not detectable in the normal kidneys, but are 
markedly induced and expressed following renal injury including AKI.4    
                       KIM-1 belongs to a large family of KIMs, otherwise known as T-cell 
Immunoglobulin Mucin proteins (TIMS), which functions as a signal or receptor for 
adhesion or signaling.5 
                         Following rapid cleavage of the protein from the apical membrane of the 
tubular epithelial cell into the tubular lumen, it becomes detectable in the urine much 
earlier than the increases in serum blood urea nitrogen and creatinine.4 
                    The present study was done to assess the levels of urinary Kidney Injury 
Molecule – 1 in patients with Acute Kidney Injury and to assess its utility as an early 
biomarker of AKI. 
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                         REVIEW OF LITERATURE 
         
                Acute kidney injury (AKI) is a clinical syndrome, which is characterized by a 
rapid decline in the glomerular filtration rate over hours to days .The term acute kidney 
injury or impairment encompasses the entire spectrum that ranges from minimal 
elevations in the serum creatinine level, to complete anuric kidney failure.6 
               AKI is a common complication of critical illness, associated with an increased 
risk of future chronic kidney disease, end stage renal disease and long term mortality, and 
it has an independent effect on the risk of death.7 
 
 HISTORICAL TRENDS 
      
              The first description of ARF, which was then termed as ischuria renalis, was 
done by William Heberden in the year 1802. With the commencement of the twentieth 
century, ARF, then termed as Acute Bright’s disease, was described in the Textbook of 
Medicine by William Osler (1909), as a consequence of toxic agents, burns, pregnancy, 
operations or trauma in the kidneys.8 
             Following the First World War, AKI was named ‘war nephritis’. The syndrome 
was forgotten until the World War II , when a paper on crush injury was published by 
Bywaters and Beall. AKI due to Acute Tubular Necrosis (ATN) was recognized in the 
1940s in the United Kingdom, where crush injury victims during the London Blitz 
developed patchy necrosis of renal tubules leading to a sudden decrease in the renal 
function. 
                 However, the credit for the introduction of the term ‘acute renal failure’ was 
awarded to Homer W.Smith in a chapter on ‘Acute renal failure related to traumatic 
injuries’ in his textbook, The kidney – structure and function in health and disease 
(1951).8 
 
EPIDEMIOLOGY 
         
                 Of late, the 20th century has witnessed a high prevalence of AKI and mortality 
associated with it. 
                 The incidence of AKI is dependent on the clinical setting as well as the 
definition that has been used in the analysis.2 As the medical care becomes more and 
more complex, the likelihood of acquiring nosocomial AKI would continue to shoot up. 
                  The incidence of AKI in the population is increasing at the rate of more than 
7% per year9. Each year about 2 million people die of AKI10. It was estimated that over 1 
of 5 hospitalized patients ended up developing AKI and an associated fourfold increase in 
the mortality was observed.6 
                    A multinational epidemiological study was conducted at 54 centres in 23 
nations in North and South America, Asia, Europe, and Australia, where 29,000 patients 
who were hospitalized in the intensive care unit were assessed. The incidence of AKI 
over a period of 16 months was found to be 5.7% (1.4% to 25.9%) out of which about 
58.9% of patients were hospitalized for medical and 41.1% for surgical problems.9 
                    AKI is very common following cardiac surgery, which represents about 
25.2% of all cases. Overall, the hospital mortality was found to be 60.3%.11 It was 
estimated that around 36% of cases with AKI required renal replacement therapy. 
                    In children, Hemolytic Uremic Syndrome was the most common cause of 
AKI, followed by gastroenteritis and glomerulonephritis causing acute tubular necrosis.  
                     In elderly patients aged above 60 years pre-renal causes of AKI among 
hospitalized patients account for 58% of all AKI cases. Post renal causes in the 
community are more common. The overall mortality is 54%. Mortality is higher (59%) in 
patients developing AKI during hospitalization when compared to AKI in the 
community(41%).11 
                     The epidemiology of AKI in developing countries differs when compared to 
developed countries in many ways. The incidence of AKI in developing countries is 
higher than in the developed areas.12 In developing countries, the presentation of AKI is 
bimodal. In large, urban areas, AKI is a hospital acquired disease, which occurs more 
commonly among older, critically ill patients with multiorgan failure and co-morbidities. 
The main cause of AKI includes ischemia due to sepsis and nephrotoxic drugs. On the 
other hand, in rural areas AKI is usually a community acquired disease, mainly affecting 
younger individuals. The causes include diarrheal diseases, infectious diseases, scorpion 
stings and septic abortions.10  
                     In developed countries, AKI is a disease of elderly with multiple co-
morbidities. Causes include overdosage of nephrotoxic drugs, hospital acquired 
infections, sepsis and complex diagnostic procedures involving intravenous contrast. 
 
CURRENT SCENARIO OF AKI IN INDIA 
                        India being a developing country, gastroenteritis and infections are the  
most common causes of AKI.13  
                         Lack of personal hygiene, poor socioeconomic status, lack of supply of 
clean water, overcrowding and lack of adequate medical facilities contribute to the high 
prevalence of AKI in our country.13   
                        In a recent publication from Institute of Medical Sciences, BHU in India, 
it was found that over a period of 26 years from 1983 to 2008, the incidence of ARF 
increased from 1.95 per 1000 admission in the period of 1983 to 1985, to 4.19 per 1000 
admission during 1996 to 2008.14 In India, it was found that the most common cause of 
AKI in the community is medical (77.5%). Other major causes were obstetric (14.2%) 
and surgical causes(8.3%).15 
                        Acute diarrheal diseases were the most common among medical causes. 
Nephrolithiasis was the most common surgical cause. Obstetric causes included puerperal 
sepsis, intrauterine death, intra-partum and post-partum hemorrhage.15 
                      Sepsis was found to be the most common contributor of in hospital 
mortality, which was most commonly complicated by urogenital infections.16 
                      The most common co-morbidities associated with AKI were found to be 
Type 2 Diabetes, followed by Hypertension and Coronary Artery Disease.15 
 
DEFINITION OF ACUTE KIDNEY INJURY 
                   Acute kidney injury is defined as a heterogenous syndrome of abrupt ( within 
hours to days ) decline in the kidney function that leads to retention of nitrogenous waste 
products such as urea and creatinine, dysregulation of fluid, electrolyte and acid-base 
homeostasis, often associated with a reduced urine output.2,14  
 
DIAGNOSIS OF ACUTE KIDNEY INJURY 
                      Acute Kidney Injury Network (AKIN) was established by a network of 
international experts who represented most of the nephrology societies in the world. This 
network included representatives from Acute Dialysis Quality Initiative (ADQI) group 
which developed an acceptable staging system called RIFLE for AKI, based on severity 
of kidney injury.17 
    The acronym RIFLE indicates  
     R - risk of renal dysfunction 
      I - injury to the kidney 
     F - failure of kidney function 
     L - loss of kidney function 
     E - end stage renal disease7 
                      RIFLE is a multilevel classification system in which the grades of severity 
in the first three levels are based on concentration of serum creatinine, decrease in the 
urine output from the baseline and degree of reduction in GFR.11,14 The next two levels 
depict the clinical outcomes based on the need for renal replacement therapy (RRT), 
reflecting the severity of prognosis.11 This system can detect patients with mildly affected  
renal function, which means a high sensitivity but limited specificity, and in those in 
whom there is marked renal dysfunction ( high specificity but limited sensitivity for 
detection).7 
 
Risk-Injury-Failure-Loss-ESRD (RIFLE) and Acute Kidney Injury Network 
                 (AKIN) criteria in Acute Kidney Injury                                      
RIFLE AKIN CRITERIA 
Risk Stage 1 Increased creatinine ×1.5 or 
GFR decrease >25% (for 
AKIN the definition also met 
if creatinine increase is 
≥0.3mg/dl. 
Urine output 
<0.5ml/kg/hr × 
6hr 
Injury  Stage 2 Increased creatinine ×2 or 
GFR decrease >50% 
Urine flow rate 
<0.5ml/kg/hr 
×12hr 
Failure  Stage 3 Increased creatinine ×3 or Urine output 
GFR decrease >75% or 
creatinine >4mg/dl (for AKIN 
definition also met if renal 
replacement therapy initiated) 
<0.3mg/kg//hr×24
hr or anuria × 
12hr.  
Loss  Persistent AKI with 
complete loss of kidney 
function and requiring 
RRT for > 4 weeks 
  
ESRD  End-stage renal disease 
requiring dialysis for 
>3months  
  
 
                     Recently it was found that even small increases in creatinine of ≥0.3mg/dl 
were associated with adverse outcomes and increased mortality. In 2007, the  AKIN 
therefore developed a classification of AKI, which was a modified form of the RIFLE 
classification18. The Risk, Injury, Failure levels became stages 1, 2 and 3. Stage 1 also 
included a rise in ≥0.3mg/dl of creatinine within 48hours. The criteria based on GFR was 
removed. The Loss and ESRD stages were also removed because they were considered as 
outcomes and not stages.19 
                     The recent KDIGO (Kidney Disease Improving Global Outcome) guideline 
for AKI stipulated yet another definition for AKI as any of the following: 
 Rise in serum creatinine by ≥0.3mg/dl within 48 hours 
 Rise in serum creatinine × 1.5 from the baseline which has occurred within the 
past 7 days 
 A urine output of <0.5ml/kg/hr for 6 hours.1 
                           These new definitions had many disadvantages because these were 
based entirely on the increases in serum creatinine or reduction in urine output, rendering 
the timely diagnosis of AKI difficult.20 There was incoherence between serum creatinine 
concentration and baseline GFR, different levels of serum creatinine between patients 
with the same extent of renal injury and delayed increases in serum creatinine relative to 
the onset of kidney injury.11  
 
PATHOPHYSIOLOGIC CLASSIFICATION OF AKI 
 
AKI can be classified pathophysiologically, depending on whether it results from, 
 Diseases causing renal hypoperfusion, yet with a preserved integrity of renal 
parenchymal tissue, the entity being termed as pre-renal state. 
 Diseases causing direct renal parenchymal damage - intrarenal or intrinsic AKI. 
 Diseases causing obstruction of urinary tract - post-renal state.21 
 
ETIOLOGY OF ACUTE KIDNEY INJURY 
 
I. PRE-RENAL CAUSES ( 40-70% of cases) 
a) Hypovolemia : haemorrhage, vomiting, diarrhea, burns. 
b) Renal hypoperfusion : NSAIDS, ACE inhibitors, abdominal aortic aneurysm, 
renal artery stenosis, hepatorenal syndrome. 
c) Hypotension : cardiogenic shock, sepsis, anaphylaxis. 
d) Oedematous states : cardiac failure, hepatic cirrhosis, nephrotic syndrome. 
II. INTRINSIC RENAL CAUSES (10-50% of the cases) 
a) Glomerular diseases : post-infectious glomerulonephritis, Henoch-Schonlein 
purpura, systemic lupus erythematosis, anti-glomerular basement membrane 
disease, disseminated intravascular coagulation. 
b) Interstitial nephritis : NSAIDS, lymphoma, sarcoidosis, tuberculosis, 
pyelonephritis. 
c) Tubular injury : ischemia, toxins – aminoglycosides, radiocontrast media, 
myoglobin, hypercalcemia, urate & oxalate crystals. 
d) Vascular : vasculitis, cryoglobulinemia, polyarteritis nodosa, thrombotic 
microangiopathy, renal artery or vein thrombosis. 
 
 
 III. POST-RENAL CAUSES (10% of cases) 
a) Intrinsic : intraluminal stone, blood clot, papillary necrosis, urethral stricture, 
prostate enlargement, bladder tumor, radiation fibrosis. 
b) Extrinsic : pelvic malignancy, retroperitoneal fibrosis.22 
 
 
 
ACUTE  KIDNEY  
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Vascular 
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Inflammation
Thrombosis
PRE-RENAL 
CAUSES
RISK FACTORS INVOLVED IN THE GENESIS OF AKI 
The most common risk factors include : 
 advanced age,  
 presence of chronic diseases such as diabetes, hypertension, heart disease and 
liver cirrhosis,22 
 presence of infections and sepsis, 
 pre-existing chronic kidney disease,18 
 failing organs such as cardiovascular and respiratory failure,23 
 surgery, mainly complex heart and vascular surgeries,  
 mechanical ventilation24 & 
 intake of nephrotoxic drugs such as NSAIDs and aminoglycosides25, 
 
PATHOGENESIS OF AKI 
                 Kidney is particularly prone to injury because of its characteristic blood supply 
and its capability of concentrating toxins.26 
Pre-renal AKI 
 Autoregulation of renal blood flow : When blood pressure falls, an intrinsic 
myogenic mechanism mediates vasodilation of afferent arterioles. To maintain a constant 
hydrostatic pressure at the glomerular capillaries, angiotensin II mediates 
vasoconstriction at the efferent arterioles.27 Autoregulation occurs upto a mean arterial 
blood pressure of 80mmHg. 
 However, when there is a marked reduction in perfusion to the kidney occurs, 
autoregulation is overwhelmed and results in renal ischemia ending up in acute tubular 
necrosis.25,28 
Following renal ischemia, the molecular responses include the following : 
a) Increased gene expression of : 
Genes involved in cell fate determination (regeneration / apoptosis)  
o Transcription factors : c-jun, c-fos 
o Cyclin dependant kinase inhibitor 
 Genes involved in inflammation : 
o Chemokines : MCP-1, IL-8 
o Adhesion molecules : ICAM-1, integrins. 
b) Decreased gene expression (loss of mature phenotype) of : 
o Preproepidermal growth factor 
o Tamm-Horsfall protein 
o Aquaporin-2 29  
 Ischemic AKI : Severe reduction in renal perfusion results in inability of tubular 
cells to maintain intracellular ATP. This leads to cytoskeletal disorganization, tubular 
epithelial tight junction disruption, endothelial cell injury, upregulation of adhesion 
molecules, shedding of components of glycocalyx, activation of leukocytes and 
coagulation  pathway and inflammation. In severe cases, apoptosis or necrosis of the cells 
occur.30 
 Acute Tubular Necrosis 
                   Morphological changes in the proximal tubular epithelium of kidney in  
response to ischemic or toxic insult include:  
1. Loss of polarity and integrity of cytoskeleton 
2. The damaged cells undergo necrosis and apoptosis 
3. Surviving epithelial cells dedifferentiate 
4. The poorly differentiated regenerating epithelial cells  migrate and spread over the 
denuded basement membrane 
5. Surviving proximal tubular epithelial cells proliferate 
6. Ultimately, the regenerating epithelial cells redifferentiate to re-establish a fully 
functional normal proximal tubule epithelium.31,32 
Tubular cell injury : 
                    The most severe injury involves the outer medulla of kidney, specifically S3 
segment of the proximal tubule and medullary thick ascending limb of distal nephron. 
Earliest damage occurs to the brush border of proximal tubular cells. The resulting loss 
in microvillar surface leads to an ineffective phagocytosis, transporter and channel 
density, hence a reduced transcellular absorption.25 Loss of tubular epithelial cells forms 
gaps in the tubular architecture. Sloughed off tubular cells and denuded basement 
membrane form intratubular casts which can obstruct the tubular lumen.21 
 
                            Figure 1 : Pathogenesis of AKI 
 
 
 
 
 
 
                      The mediators of tubular cell injury include reactive oxygen species, 
intracellular calcium influx, phospholipase A2, nitric oxide, complement and cell 
mediated cytotoxicity.28 
Hemodynamic vascular alterations : 
                  Renal injury can result in profound reduction in the GFR. This is due to 
afferent arteriolar vasoconstriction which causes a drop in the filtration pressure. This 
could be a result of endothelial cell injury, resulting in an imbalance in the vasoactive 
substances, with a predominant vasoconstrictive effect.21 The vasoconstrictor substances 
which have been implicated in this include angiotensin II, adenosine, endothelin-1, 
thromboxane A2, leukotrienes C4 and D4, prostaglandin H2 and sympathetic nerve 
stimulation.28  
                 Furthermore, ischemic and toxic injury increases the release of endothelin 
(ET-1) from endothelial cells, which is the most potent vasoconstrictor known. In AKI, 
the decreased neutral endopeptidase results in decreased degradation of ET-1, hence 
explaining its sustained increase.27 The major effects of ET-1 include: 
o Renal vasoconstriction and mesangial cell contraction 
o Mitogenesis and proliferation of mesangial cells 
o Recruitment and activation of leukocytes.25 
                         In AKI, reduced sodium reabsorption by the proximal tubules increases 
the concentration of sodium chloride which is delivered to the macula densa. This 
activates the renin-angiotensin system resulting in a decline in GFR. This sequence of 
events is called tubuloglomerular feedback.27 
 Tubular obstruction : 
                    Tamm-Horsfall protein can polymerise to form casts by further trapping the 
tubular cell debris and denuded basement membrane, causing tubular obstruction.21  
                   Integrins are heterodimeric (α3β1) glycoproteins which recognize the RGD 
sequence (arginine-glycine-aspartate) in matrix proteins, which mediates cell-to-cell 
adhesion. Oxidative stress causes depletion of integrins on the cellular basal surface, 
leading to loss of anchorage to the basement membrane and desquamation of cells. 
Movement of integrins from basolateral location to the apical membrane results in 
detatchment of tubular cells and further promiscuous adhesion of sloghed off cells to the 
cells remaining in situ, thus initiating tubular obstruction.27 
 
Tubular backleak : 
                   In the setting of loss of epithelial cells, loss of adhesion molecules (E-
cadherins) and loss of tight junction proteins (ZO-1, occludin ) , which maintain 
separation of tubular filtrate from surrounding interstitium, the glomerular filtrate which 
enters tubular space will leak back into the renal interstitium and gets reabsorbed into 
systemic circulation resulting in a decline in the effective GFR.21  
Role of nitric oxide : 
               In AKI, cytokines induce the expression of iNOS leading to an increase in the 
production of nitric oxide. On the other hand, secondary to endothelial dysfunction eNOS 
is inhibited. This imbalance between eNOS and iNOS, with a relative decrease in eNOS, 
increases susceptibility to microvascular thrombosis due to loss of thrombogenic property 
of endothelium, enhances neutrophil adhesion to the endothelium and vasoconstriction. 
              Increase in iNOS induces tubular epithelial cell injury, enhances motility of 
neutrophils and vasomotor response is attenuated.25  
              Following ischemia-reperfusion injury, generation of NO and superoxide 
radicals result in the formation of peroxynitrite (OONO ̄ ) which is cytotoxic causing lipid 
peroxidation and DNA damage.27 
Endothelial cell injury : 
                      In response to acute renal ischemic and oxidant injury, endothelail cells 
undergo swelling, overexpression of adhesion molecules (ICAM-1) with an increased 
leukocyte - endothelial cell interaction and blunting of vasorelaxation due to decreased 
eNOS and vasodilatory prostaglandins.28 The normal architecture of endothelial barrier is 
lost creating gaps between confluent endothelial cells due to loss of tight junctions. The 
normal actin cytoskeleton of endothelial cells is lost due to ATP depletion which 
reversibly disrupts F-actin structures.25 
Role of inflammation : 
                   Neutrophils and other inflammatory cells play an important role in the 
pathogenesis of ischemic AKI. The series of events involving adherence of leukocytes to 
the vascular endothelium involves adhesion molecules including selectins, mucins, 
endothelins and immunoglobulin superfamily.25  
                  The earliest feature of inflammation is margination of neutrophils to the 
vascular endothelium. Activation of leukocytes to release cytokines involves reception of 
signals through circulating chemokines or through direct interaction with endothelium. 
Once activated, the leukocyte integrins undergo conformational change and bind to 
endothelial ligand for firm adhesion. This firm adhesion is imparted through interactions 
between endothelial cell integrins and ICAM-1.21,25 
Role of inflammatory cytokines : 
                  In response to acute ischemic or toxic injury, renal tubular epithelial cells 
express many proinflammatory cytokines which include TNF-α, interferon-γ, 
granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukins 1, 2 and 18 ; 
and chemokines such as macrophage inflammatory protein-1 (MIP-1), monocyte 
chemotactic protein-1 (MCP-1), and RANTES, which promote infiltration of 
leukocytes.25,28 
Disruption of actin cytoskeleton : 
              The actin cytoskeleton in PCT forms a terminal web layer below the apical 
membrane. A core of F-actin filaments extend from the web layer to the tip of microvilli, 
hence maintaining the integrity of brush border. 
              Ischemia results in ATP depletion in the cells, which in turn disrupts and 
redistributes the F-actin core to form membrane-bound vesicles or blebs. This disruption 
is due to depolymerisation mediated by actin binding protein called Actin 
Depolymerisation Factor (ADF) or cofilin, which is normally inactive in its 
phosphorylated form. Ischemia which causes ATP depletion dephosphorylates and 
activates ADF. ADF then relocalises to the apical membrane and causes 
depolymerisation, capping, severing and F-actin nucleation.33  
                   Actin binding proteins such as spectrin and ankyrin are degraded by the 
activation of cyateine protease calpain. This results in abnormal translocation of sodium-
potassium-ATPase and other proteins subsequently resulting in loss of cellular polarity. 
This impairs the normal reabsorption of solutes with increased delivery of sodium 
chloride to the distal nephron and activation of tubule-glomerular feedback.28 
 Cell necrosis and apoptosis : 
                  The severity and  duration of renal tubular cell injury determines the 
mechanism of cell death. Cells suffering lethal injury undergo cell death by apoptosis or 
necrosis. Particularly necrosis occurs when there is severe depletion of energy stores of 
the cells with subsequent metabolic shutdown. 
The biochemical mechanisms resulting in cell necrosis include: 
 Severe intracellular ATP depletion 
 Generation of reactive oxygen species 
 Avtivation of enzymes such as phospholipases, proteases and endonucleases. 
                 During apoptosis, mitochondria undergoes certain irreversible changes such as 
collapse of electron transport chain and release of  apoptosis-inducing factor and 
cytochrome C which are indispensable for the activation of DNases and downstream 
caspases respectively. 
  
 Figure 2 : Role of inflammation and disruption of cytoskeleton 
     
    
      
Post-renal AKI 
                Ureteric obstruction causes ARF when there is either a bilateral blockage at any 
level of ureters, or unilateral blockage in a solitary functioning kidney. Obstruction may 
be intraluminal or extraluminal. The most common cause is structural or functional 
obstruction of neck of the bladder.25 
                   In the early stages, the glomerular filtration continues to be normal. This 
leads to an increase in intraluminal pressure of the renal tubules, upstream of the site of 
obstruction. The proximal ureter, pelvis and calyses gradually start distending, and 
eventually GFR declines. Furthermore, vasoconstriction of arterioles supervenes, further 
declining the GFR.21 
 
CLINICAL COURSE OF AKI 
I.  Initiation phase 
It is the phase wherein the patient is exposed to ischemia or toxins, with an evolving renal 
parenchymal injury, but not established, hence potentially preventable.21 This period lasts 
for hours to days, and is characterized by :  
 Loss of  brush border, destruction of cytoskeleton 
 Loss of cellular polarity,  detatchment of tubular cells 
 Formation of casts & reduction of glomerular filtration11  
II.  Maintenance phase : 
This phase is characterized by an established parenchymal injury and GFR stabilizes at a 
value of 5-10ml/min. It typically lasts for about one to two weeks.21 This phase is 
characterized by : 
 Microvascular changes, imbalance between vasodilatory and vasoconstrictive 
substances 
 Coagulation cascade activation and inflammation11 
III. Recovery phase 
                   This is the period when renal function starts recovering by regeneration of 
renal tissue. It is typically heralded by a gradual rise in urine output, fall in serum 
creatinine concentration and osmotic dieresis-induced by filtered urea.21 Regenerating 
cells colonizing the injured areas can be derived from three sources: 
a) Dedifferentiated surviving epithelial cells 
b) Resident kidney stem cells 
c) Bone marrow derived stem cells which migrate to the kidney and transdifferentiate 
to form mature tubular epithelial cells.29  
 
ACUTE KIDNEY INJURY IN SPECIAL SITUATIONS 
 
AKI FOLLOWING SNAKE BITE  
                   Snake bite is a common occupational hazard among farmers and agricultural 
workers in the rural areas of developing countries. Among venomous snakes, in India 
viper bites are more common.34 The two widely distributed vipers causing ARF in India 
are Russel’s viper and Echis carinatus.35  
                  The kidneys being highly vascularised organs, are highly susceptible to the 
venom toxins of snake. A wide range of renal manifestations have been observed which 
include  
o   Acute tubular necrosis (most common),  
o   Acute tubulointerstitial necrosis,  
o   Renal cortical necrosis,  
o   Vasculitis 
o   Mesangiolysis  
o   Glomerulonephritis  
o   Hematuria , proteinuria, myoglobinuria.36 
                 AKI due to snake envenomation is mostly due to acute tubular necrosis 
(100%) and acute cortical necrosis (25%). Occasionally glomerular lesions (30%) are 
also observed.37 Following envenomation AKI develops within one to two days.36 
Usually kidney injury following snake bite is reversible, but if acute cortical necrosis sets 
in, it may end up in incomplete recovery.34 
                       Factors that contribute to pathogenesis of renal injury include bleeding, 
hypotension, circulatory collapse, disseminated  intravascular coagulation, intravascular 
hemolysis, direct nephrotoxicity of venom, microangiopathic hemolytic anaemia, 
hemoglobinuria, rhabdomyolysis.34 
Nephrotoxicity of the venom : 
                        AKI induced by snake venom may be either due to its direct cytotoxicity 
on the renal structures or a secondary response of systemic envenomation triggered by 
inflammation, release of cytokines such as TNF-α, interleukins and vasoactive substances 
like nitric oxide, bradykinin, histamine, and eicosanoids. These ultimately reduce the 
renal blood flow and generate an ischemic process and reduced cellular oxygen delivery 
leading to cell injury and necrosis. Snake venom metalloproteinases, phospholipases A2, 
serine proteases, hyaluronidases, esterases, L-amino oxidases and bradykinin-potentiating 
peptides are responsible for releasing vasoactive and inflammatory substances.36 
                    Hypotension may be due to bleeding into tissues or externally, release of 
bradykinin, depression of medullary vasomotor centre, myocardial depression, arteriolar 
vasodilatation. Ultimately these factors result in ischemic ARF. 
                    Intravascular hemolysis is mediated by phospholipase A2 and ‘direct lytic 
factor’. Phospholipase A2 causes either direct hemolysis of red cell membrane or 
indirectly by the production of lysolecithin which is a strong hemolytic substance. Free 
hemoglobin levels greater than 200mg/dl in the plasma is toxic to the renal tubular cells. 
In the setting of hemoglobinuria, ARF sets in particularly when dehydration, hypotension 
or hemorrhage supervene.35 
                  Disseminated intravascular coagulation : 
Venom of E. carinatus directly activates the conversion of prothrombin to thrombin. 
Russel’s viper venom induces thrombin formation by activating factor X in the presence 
of calcium ions and factor V.35 
    The formation of fibrin thrombi in the renal glomerular capillaries and 
microvasculature contributes to the renal dysfunction. 
Rhabdomyolysis :  
                  Myoglobin toxicity following rhabdomyolysis causes renal injury by 
following mechanisms – 
 Myoglobin causes renal vasoconstriction by acting as nitric oxide scavenger by 
directly binding NO. This results in hypoperfusion and ischemic injury. 
 Myoglobin precipitates within the renal tubules forming intraluminal obstructive 
casts. This precipitated myoglobin may undergo degradation to form free heme and 
iron, which are potential agents causing renal injury by generating ROS.  
 
 
SEPSIS AND ACUTE KIDNEY INJURY 
                     Sepsis is defined as “ a severely dysregulated inflammatory response to 
infections characterized by dysfunction of end organs away from the primary site of 
infection.”38 
                     The hallmark of any form of sepsis is activation of the immune response 
system of host, as a response to exotoxins and cell wall components of the bacterial 
organisms.25 
                      Humoral mediators of sepsis include bacterial lipopolysaccharides, 
microbial DNA and lipopeptides, lipoteichoic acid and peptidoglycan which trigger the 
expression of toll-like receptors (especially TLR-4). This activates certain signal 
transduction pathways which exacerbate the generation of various cytokines.39 
                      The pathogenesis of sepsis-induced AKI is multifactorial which includes 
hemodynamic alterations, activation of pro- as well as anti-inflammatory pathways, 
endothelial dysfunction, coagulation activation and immunological dysregulation, all of 
which culminate in multi-organ damage.38,40 
 Renal perfusion : A fundamental feature of sepsis is arterial vasodilatation 
associated with a decrease in the systemic vascular resistance.38 Regional redistribution 
of blood flow to the kidney away from the medulla, while favouring the cortex occurs 
during sepsis. This phenomenon is termed ‘cortico-medullary redistribution’.41 
                   The reversible mechanisms of sepsis-induced hypovolemia include 
increased vascular permeability with leakage of fluid into the interstitium, increased 
venous pooling and septic vasoplegia-induced hypotension.40 
                         In addition, hypoxia, acidosis and mechanical ventilation, especially 
PEEP cause vasoconstriction. Increase in body temperature associated with sepsis leads 
to ATP loss and worsens the ischemic injury.41 
                            Additional contributing factors include efferent arteriolar vasodilatation, 
peri- glomerular shunting between the afferent and efferent arteriole, neutrophil 
accumulation primed by endotoxin, release of vasoactive substances such as 
adenosine, endothelin and thromboxane A2 .42 
 Inflammation : AKI following sepsis is heralded by the induction of a variety of 
inflammatory cytokines, thrombogenic substances, biologically active mediators and 
arachidonate metabolites.  
                    The major mediators of cytokine-induced AKI are TNF and IL-1, which 
induce neutrophil aggregation, vasoconstriction, ROS production and thrombosis by 
inducing tissue factor. These cytokines also have the ability to induce mesangial and 
endothelial production of vasoactive substances.43  
                    Sepsis induces oxidative stress. The propagation of ROS cascade is 
accompanied by a decrease in the endogenous ROS scavengers such as superoxide 
dismutase in the kidney during endotoxemia. The reactive species also scavenge nitric 
oxide producing peroxynitrite radicals, which add on to the renal injury. Of late, it has 
been found that ROS induce the endothelial secretion of multimers of  von Willibrand 
factor  and ADAMTS-13 inhibits the proteolysis vWF.44 
 Cellular mechanisms :  
                     The evolution of sepsis is characterized by dysfunction of tubular 
epithelial tight junctions leading to back-leak of tubular fluid into the interstitium. 
Tubular cast formation occurs following loss of cellular adhesion to the basement 
membrane.43 
                       The renal tubular cells die by two mechanisms, apoptosis and necrosis. 
The necrotic cells release ATP which directly activate Nrlp3 inflammosome  via P2X7 
receptor, further accelerating the tissue damage.45 
                         During acute renal injury the death receptors, Fas-L and TNFR-1 are 
expressed which contribute to the apoptotic mechanism of cell death. 
                         Yet another proposed mechanism of renal injury following sepsis is 
mitochondrial hibernation which results in an inadequate production of ATP due to a 
decline in the respiratory chain activity.30 
 Coagulation cascade : 
                          In response to LPS and TNF, the expression of tissue factor is induced. 
TF binds activated  FVII,  which activates FX that cleaves prothrombin to form 
thrombin and finally the formation of fibrin. Tissue inflammatory response is enhanced 
by this cascade.43 
 
CONTRAST-INDUCED AKI 
                   It presents as an acute GFR reduction by 24 to 48 hours after administration 
of intravenous contrast.11 The main pathophysiological mechanisms postulated are a 
combination of acute renal vasoconstriction, medullary ischemia and ROS generation 
causing a direct renal tubular injury. A biphasic hemodynamic response is observed 
where an initial vasodilation is followed by sustained vasoconstriction due to vasoactive 
substances released from endothelial cells. This results in cortico-medullary redistribution 
of renal blood flow.21,46 
 
RHABDOMYOLYSIS 
                       The most common causes of rhabdomyolysis causing AKI are trauma, 
ischemia, drugs, metabolic abnormalities, genetic defects and infections. The spectrum of 
rhabdomyolysis leading to myoglobinuria and hence renal failure is related to 
vasoconstriction, oxidant stress causing tubular cell injury and tubular obstruction by cast 
formation.2 
 
AKI IN PREGNANCY 
                  
                   Urinary tract infections which are the most common pregnancy related 
complications can progress to pyelonephritis. Infection following abortion can cause 
renal injury by sepsis, hemorrhage, hypotension and DIC. 
                    Post-partum hemorrhage, pre-eclampsia, abruption placenta, amniotic fluid 
embolism are third trimester and post-partum complications which cause AKI by 
ischemia causing bilateral cortical necrosis.47 
 
DRUG-INDUCED AKI  
 
The factors that increase the vulnerability of kidneys to toxins are 
 A wide range of drugs are excreted by the kidneys. Its concentrating mechanisms are 
responsible for the exposure of the renal tubular cells to intracellular accumulation of 
massive concentrations of drugs. 
  Drugs also undergo metabolism and biotransformation by the kidney, resulting in 
formation of toxic compounds. 
The mechanisms of drug-induced nephrotoxicity include acute tubular cell injury, 
intratubular obstruction, hemodynamic alterations, acute interstitial nephritis, thrombotic 
microangiopathy, rhabdomyolysis, hypersensitivity vasculitis and osmotic nephrosis.48  
 
ACUTE INTERSTITIAL NEPHRITIS 
                    AIN is characterized by immune – mediated tubule-interstitial injury caused 
by drugs, autoimmune disorders or infections. 
                   The drug-induced hypersensitivity reactions result in AKI by inducing 
allergic response in the interstitium and tubules of kidney, sparing the glomeruli. 
                    Infections caused by Legionella pneumophila, leptospira, cytomegalovirus, 
hepatitis B, HIV or streptococci can cause AIN by releasing chemokines, leading to 
infiltration of leukocytes within the interstitium.49 
 
AKI IN CANCER 
AKI in patients with cancer is due to 
 Nephrotoxic chemotherapeutic agents such as mitomycin c, platinum compounds, 
gemcitabine, ifosfamide and methotrexate. 
 Tumor lysis syndrome is particularly seen in patients with large tumors having a 
cellular turnover rate following cytotoxic therapy. Massive amounts of intracellular 
contents are released into the systemic circulation, leading to accumulation of uric acid 
and cytoplasmic contents (potassium, phosphorus) which exceeds the excretory 
capacity of kidney. AKI is secondary to tubular obstruction caused by intratubular 
precipitation of uric acid and xanthine, resulting in acute urate nephropathy and acute 
nephrocalcinosis. 
 In patients with multiple myeloma, AKI results due to myeloma cast nephropathy, 
glomerular infiltration with light chains and amyloid deposition.50 
 
ACUTE PHOSPHATE NEPHROPATHY 
                        It is a complication following preparation for colonoscopy and bowel 
surgery with oral phosphate solution as bowel cathartic. The pathogenesis involved is a 
significant increase in the serum phosphate concentration, with a simultaneous depletion 
of intravascular volume, which causes precipitation of calcium phosphate salts within 
renal tubules causing direct injury.33  
 
AKI  FOLLOWING CARDIAC SURGERY 
                  The risk factors for developing post-operative AKI includes pre-operative 
renal function, diabetes, age, duration of cardiac bypass, blood transfusion, vascular 
surgery and poor cardiac function. Renal athero-embolism can result from aortic 
clamping and instrumentation. Activation of neutrophils, complement and fibrinolytic  
systems occur following cardiac bypass. Furthermore, peri-operative left ventricular 
dysfunction and myocardial infarction can hamper renal perfusion.28 
 
AKI IN NEPHROTIC SYNDROME 
The proposed mechanisms of AKI following nephrotic syndrome include: 
 Hypovolemia due to reduced plasma oncotic pressure 
 Reduced GFR secondary to hypoproteinemia, exacerbated by inhibition of 
prostaglandin synthesis  by NSAIDs 
 Hypercoagulable state accompanying nephrotic syndrome predisposes to renal vein 
thrombosis.51 
 
ORGAN CROSS TALK DURING AKI :  
 
                         AKI is a systemic syndrome which can cause potentially devastating 
effects on other organs. 
 
1)  AKI could be associated with acute lung injury characterized by an increase in 
permeability of  pulmonary vasculature and microvascular inflammation. Uremic toxins 
could result in downregulation the epithelial sodium channels of lung.25 
2)   There could also be a cross talk between kidney and bone marrow following acute 
ischemia characterized by an increase in the levels of Granulocyte- Colony Stimulating 
Factor mRNA and protein and an increase in the activity of myeloperoxidase.25 
3)     Kidneys produce IL-6 following injury which can stimulate the kupfer cells of liver 
to produce IL-10, augmenting further inflammatory damage to the organ. 
4)   Furthermore, cross talk between heart and kidney could occur, which mainly involves  
tumor necrosis factor–α, IL-1, ICAM-1 mRNA and apoptotic mechanisms.21 
 
CONSEQUENCES & COMPLICATIONS OF AKI 
  
                    Consequences include significant risk of developing chronic kidney disease 
especially stage 4 CKD, long term dialysis dependence, increased mortality, and personal 
and community costs.10, 30 
 
   Complications include : 
1)Metabolic complications : hyperkalemia, metabolic acidosis, hyponatremia, 
hypocalcemia, hyperphosphatemia, hypermagnesemia, hyperuricemia, uremia. 
2)Cardiovascular complications : pulmonary edema, arrhythmias, pericarditis, 
pericardial effusion, pulmonary embolism, hypertension, myocardial infarction. 
3)Gastro-intestinal complications: nausea, vomiting, gastrointestinal hemorrhage. 
4)Neurological complications : neuromuscular irritability, asterixis, seizures. 
5)Hematological complications : bleeding and anemia due to inhibition of 
erythropoiesis, hemolysis, hemodilution and reduced RBC survival time. 
5)Infections : pneumonia, septicemia, urinary tract infections. 
7)Malnutrition due to loss of appetite, increased catabolism and nutrient losses in 
dialysate. 
8)Other complications: hiccups, elevated parathormone, low total T3  and T4.21,25 
             
            
                    
 
 
 
 
           
 
 
 
 
 
 
                        KIDNEY INJURY MOLECULE - I 
     
                    Kidney injury molecule-1 (KIM-1) is a transmembrane renal tubular protein 
whose expression is markedly induced in acute as well as chronic renal disease. The 
cDNA for this membrane protein was first discovered by Ichimura et al, from post-
ischemic kidney of rat.4 
                          KIM-1 is one of the members of immunoglobulin gene superfamily (IgSF), 
which is structurally most closely identical to ‘mucosal addressin cell adhesion molecule-
1’ (MAdCAM-1)52 
 
STRUCTURE OF KIM-1 
           
                   KIM-1 is a type-1 membrane glycoprotein with a molecular weight of 
104kDa and consists of 
 An extracellular part, containing a novel six-cysteine immunoglobulin-like domain, 
two putative sites of N-glycosylation and a mucin domain which is rich in 
Threonine/Serine-Proline, where O-glycosylation of the polypeptide chain can occur.3 
 A transmembrane domain, and 
 A cytoplasmic domain which is relatively short and contains a highly conserved 
tyrosine kinase phosphorylation site which is phosphorylated by  tyrosine. This 
indicates that KIM-1 could act as a signaling molecule.4,53 
                          The Ig-like domains mediate cell surface protein interactions which are 
responsible for interactions between cell to cell and cell to matrix.32 
                          Jentoft proposed the “lollipop on a stick” model which states that the 
mucin domain functions as a configurational domain which extends the Ig-like domain 
sufficiently above the plasma membrane, like a stalk. Mucins could be involved in cell 
adhesion and also protect the epithelial cellular surface.32,52 
 
Molecular Structure of KIM-1 
                        
                        The open reading frame of KIM-1 consists of 307 amino acids. The 
signal sequence is of 21 amino acids, the trans-membrane spanning domain of 23 amino 
acids from 235 to 257 and the cytoplasmic portion consists of 50 amino acids. 
                         The extracellular domain consists of 213 amino acids. It contains two 
distinct domains. Within its amino terminal is a region which is homologous to the 
variable regions of IgSF with respect to two cysteine residues ( Cys37 and Cys108 ). In 
addition to these two residues, KIM stands unique due to the presence of four additional 
cysteine residues in its Ig domain. The mucin domain is from amino acids 131-201. 52 
                The two putative N-glycosylation sites are found between the mucin domain 
and transmembrane domain.52 
 
 
                      Figure 3 : Structure of KIM-1 
       
         
        
 
 TYPES OF KIM-1 
 KIM-1 was first discovered in African green monkeys as the cellular  receptor for 
hepatitis-A virus (HAVcr-1). Subsequently two homologs of KIM-1 were cloned in 
humans. 
a) KIM-1a (hepatic form) : cloned from liver as the homolog of KIM-1 
b) KIM-1b (renal form) : cloned from kidney as the homolog of HAVcr-1 
                    These two homologs are splice variants which differ in their C-terminal part 
of cytoplasmic domain.54 
                     KIM-1 was recently discovered to be expressed also in activated Th-1 and 
Th-2 lymphocytes. Hence it is othervise called as Tim-1 ( T-cell immunoglobulin and 
mucin-containing molecule). Tim-1 is a member of closely related molecules, with 8 
types found in mice (Tims1-8) and 3 in humans (Tims1, 3 and 4). Tim-1 is mainly 
expressed in Th-2 cells and involved in airway hyper-responsiveness and atopic disease, 
whereas Tim-4 in dendritic cells and macrophages. They act as co-stimulating molecules 
positive regulators of activity of T-cells.54,55 
 
SHEDDING OF THE ECTODOMAIN: 
                         KIM-1 is dramatically upregulated in  dedifferentiated epithelium of 
proximal tubules of the kidney, as an early response to injury.53 Subsequently, the heavily 
glycosylated ectodomain of KIM-1 is shed from the surface of the cells into the tubular 
lumen.3 This surface proteolytic cleavage of the transmembrane glycoprotein, leads to 
release of a soluble form of 90kDa into the extracellular matrix , leaving a C-terminal 
stalk associated with the cell.32  
                             This process is found to be regulated by mitogen activated protein kinase 
(MAPK) signaling pathway, which is induced by cell stress.4 The enzymes that 
participate in cleavage are matrix metalloproteinases (MMPs) or members of the ADAM 
family (a desintegrin and metalloproteinase).32  
                      The ectodomain that is shed in the urine has been found to be sufficiently 
stable for a prolonged period of time.56 This adds to the value of KIM-1 as a biomarker 
because the expression of KIM-1 in the tissue is closely correlated with its excretion in 
the urine.54  
                      The function of the ectodomain is that it interacts with integrins in the 
apical membrane of tubular cells, restraining their depolarization. This prevents the 
exfoliated cells from getting attached to one another, producing tubular obstruction by 
forming casts.4 
 
KIM-1 IN KIDNEY INJURY 
                   KIM-1 has been discovered as the most highly expressed proximal tubular 
protein in response to renal injury. Following an acute insult, KIM-1 mRNA rapidly 
translates to generate massive amounts of the protein which localizes on the proximal 
tubular apical membrane.    
                         In humans following ischemia or toxic renal injury, all three segments of 
proximal tubule show increased KIM-1 expression, although it is most prominently 
expressed in the S3 segment, being most susceptible to injury due to ischemia or 
toxins.4,57 The  expression of KIM-1 gene in the kidney correlates with the expression of 
KIM-1 protein in the kidney as well as urine.58            
         The concentration of KIM-1 in the urine of  healthy humans is less than 1ng/ml.  
 
FUNCTIONAL ROLE OF KIM-1 
 
a) Role as a scavenger receptor : KIM-1 has been established as a functional 
phosphatidyl serine receptor which confers the properties of phagocytosis on the 
epithelial cells in the post-ischemic kidney. KIM-1 ctransforming the epithelial cells of 
the tubule into semiprofessional phagocytes. This involves not only binding to the cell 
surface, but also triggers internalization.26 These transformed cells clear off the necrotic 
and apoptotic cell debris from the tubular lumen, which is critical for remodeling 
following injury, hence relieving intratubular obstruction.4  
    KIM-1 has been found to be the first epithelial cell scavenger receptor which is found 
in non-myeloid cells.3,26 KIM-1 also has the properties of macrophage scavenger receptor 
type B that binds oxidized LDL.57 
b) Anti-inflammatory role : KIM-1 has an anti-inflammatory role by mediating 
phagocytosis. This protective effect is mucin domain-dependant. 
    KIM-1 interacts with p85 and subsequently PI3K mediates the downregulation of 
NFkB. This culminates in a decline in the TLR-4 expression, reduced pro-inflammatory 
cytokines and macrophage activity. This protects the kidney by dampening inflammation 
and innate immunity.59 
c) Role in immunity : In immune system, KIM-1/TIM-1 mediates the activation of 
Th1, Th2 and Th17 differentiation by acting as surface receptor on T-cell, 
interacting with antigen presenting cells. It also functions as a receptor which 
activates the natural killer T-cells, dendritic cells and B-cells.5,60 
d) Adhesion molecule : KIM-1 has many roles in epithelial function. It interconnects 
the cells to one another and also tethers the epithelial cells to the extracellular 
matrix.4 
e) Role in regeneration and repair : Following an acute insult, KIM-1 plays an 
important role in maintaining morphological and functional integrity of the 
kidney.54 The surviving epithelial cells undergo cell locomotion, proliferation and 
dedifferentiation mediated by KIM-1 which is necessary for regeneration and 
repair of the injured epithelium.31 KIM-1 is involved in the migration of 
dedifferentiated cells, hence facilitating the reconstitution of continuity of 
epithelial layer.4,32 
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                          AIM OF THE STUDY 
 
 
1. To estimate urinary KIM-1 level in cases of acute kidney injury. 
2. To compare the level of urinary KIM-1 with serum creatinine and blood urea and 
to prove the utility of urinary KIM-1 as an early biomarker of acute kidney injury. 
 
 
 
 
 
 
 
 
 
 
  
MATERIALS AND 
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                                MATERIALS AND METHODS 
    
                             The study was conducted at Thanjavur Medical College, Thanjavur, 
after getting approval from the Ethical Committee of Thanjavur Medical College, 
Thanjavur. 
                              The study is a cross-sectional and analytical study which was 
conducted from January 2014 to September 2015. A total of 100 subjects were chosen. 
Both males and females in the age group above 18 years were included and an informed 
consent was obtained from all of them. The study population included two groups.  
                             One group consists of 50 patients who were admitted for snake bite, 
and the other group consists of 50 patients who were admitted with sepsis. The patients 
who did not develop AKI were considered as controls. 
 
INCLUSION CRITERIA : 
 Patients admitted within 12 hours of snake bite. 
 Patients who developed sepsis with the presence of a septic focus. 
 Age > 18 years 
 
EXCLUSION CRITERIA : 
 Chronic kidney disease 
 Snake bite and sepsis patients with elevated serum creatinine on admission 
 Known hypertensive on treatment 
 History of diabetes mellitus 
 History of Polycystic Kidney Disease 
 Nephrotic syndrome 
 
STUDY PROTOCOL 
A detailed history was elicited for 
 Co-morbid diseases and concomitant drug intake  
 History of snake bite, time and site of bite, species of snake, native treatment, 
treatment before hospitalization. 
 History of reduced urine output 
 History of infections, fever. 
Clinical examination:  
                      A thorough physical examination was done to look for local and systemic 
features of envenomation like fang marks, cellulitis, bleeding from the site of bite, local 
necrosis, blistering, gangrene, regional lymph node enlargement and features of gum 
bleeding, epistaxis, ecchymosis. 
                     A systemic examination was done to assess for the presence of respiratory, 
genitourinary, gastrointestinal, central nervous system or musculoskeletal infections.  
                   All vital signs were looked for. Features of uremic symptoms were looked 
for. 
SAMPLE COLLECTION  
 
Urine :  
     Urine samples were collected in sterile tubes. The samples were centrifuged at 2000 
rpm for about 20 minutes. Supernatant was carefully collected and stored by freezing at -
20°C. When sediments occurred during storage, again centrifugation was done.  
 
Serum :  
    The serum was allowed to clot for 20 minutes at room temperature. Then the samples 
were centrifuged at 2000rpm for 20 minutes. Supernatant was collected carefully and 
stored at -20°C.  
 
INVESTIGATIONS : 
1. Urinary KIM-1 
2. Serum creatinine 
3. Serum urea 
4. Complete blood count 
5. Clotting time 
 
 
 
ESTIMATION OF URINARY KIDNEY INJURY MOECULE – 1 
 
METHODOLOGY :  
    enzyme-linked immune sorbent assay (ELISA) 
 
PRINCIPLE & PROCEDURE:  
                    The basis of ELISA used by this kit is Biotin double antibody sandwich 
technology to assay human KIM-1. Samples and calibrators containing KIM-1 were 
added to the wells that are pre-coated with KIM-1 monoclonal antibody and then 
incubated. Then biotin-labelled anti-KIM-1 antibody was added which unites with 
strptavidin-HRP forming immune complexes. The unbound enzymes were removed after 
incubation by washing. Substrates A and B were added which changes the colour of the 
solution to blue and then yellow by the effect of acid. The shades of solution positively 
correlate with the concentration of Human KIM-1. 
 
MATERIALS SUPPLIED IN THE KIT: 
1. Standard solution (12.8ng/ml) - 0.5ml 
2. Standard dilution -  3ml 
3. Coated ELISA plate - 12 wells × 8 tubes 
4. Streptavidin-HRP - 6ml 
5. Washing concentration (30X) - 20ml 
6. Anti-KIM-1 antibodies labeled with biotin - 1ml 
7. Chromogen solution A - 6ml 
8. Chromogen solution B - 6ml 
9. Stop solution - 6ml 
Other materials required were 
10.  37°C incubator 
11.  Precision pipettes and disposable pipette tips 
12.  Disposable tubes for sample dilution 
13.  Standard enzyme reader 
14.  Distilled water 
15.  Adsorbent paper 
  
PREPARATION OF REAGENTS  
 All samples and reagents were brought to room temperature which took about 30 
minutes. Specimens were mixed thoroughly by gentle inversion and visible 
particulate matter was cleared by low speed centrifugation. 
 Wash solution : 30X wash solution was diluted by pouring the total contents  of 
the bottle (20ml) into a 1L graduated cylinder and 580ml of deionised water was 
added to make a final volume of 600ml. It was then thoroughly mixed. 
 Dilution of standard solution : The kit had a standard of original concentration 
which was supposed to be diluted in small tubes by following the instructions: 
 Standard No.5 6.4ng/ml 120μl original standard + 120μl standard diluent 
Standard No.4 3.2 ng/ml 120μl Standard No.5   + 120μl standard diluent 
Standard No.3 1.6 ng/ml 120μl Standard No.4   + 120μl standard diluent 
Standard No.2 0.8 ng/ml 120μl Standard No.3   + 120μl standard diluent 
Standard No.1 0.4 ng/ml 120μl Standard No.2   + 120μl standard diluent 
 
 
 
 
 
 
 
12.8 ng/ml     6.4ng/ml   3.2ng/ml  1.6ng/ml  0.8 ng/ml  0.4 ng/ml 
 
 
 Streptavidin-HRP : ready to use 
 Biotin labeled Anti KIM-1 antibodies : ready to use 
 Chromogen solutions A and B : ready to use 
 Stop solution : ready to use 
 
 
STANDARD 
ASSAY PROCEDURE 
 The number of stripes needed was decided by the number of samples to be tested 
and by that of standards. 
 Sample injection : 
1. Blank well : no sample, anti KIM-1 antibody or streptavidin-HRP was 
added to the blank well. Chromogen solutions A and B, and stop solution 
were added. 
2. Standard solution well : 50μl standard and 50μl streptavidin-HRP were 
added. Since the biotin antibodies are already united in the standard, they 
need not be added. 
3. Sample well : 40μl sample, 10μl biotin labeled KIM-1 antibodies and then 
50μl streptavidin-HRP were added. Then the ELISA plate was covered with 
a seal plate membrane.  
The plate was shaken gently to mix them up and then it was incubated at 37°C for 60 
minutes.  
 Washing : The seal plate membrane was carefully removed, liquid drained and the 
remaining liquid shaken off. Each well was filled with 350μl wash solution. After 
standing for 30 seconds, the liquid was drained. To blot the ELISA plate, it was 
pat hard on bibulous papers on  the test bed, several times downward.  The 
procedure was repeated 5 times. 
 Color development : First,  50μl chromogen solution A was added to each well, 
and then 50μl chromogen solution B was added to each well. They were mixed by 
gentle shaking. Incubation was done for 10 minutes at 37°C away from light for 
the color to develop. 
 Stop : To stop the solution 50μl stop solution was added to each well. At this 
moment, there was an immediate change in color from blue to yellow. 
 Assay : Taking blank as zero, the absorbance (OD) of each well was measured at 
450nm wavelength within 10 minutes after adding the stop solution.  
 According to the concentration of standards and their corresponding  OD values, 
the linear regression equation of standard curve was calculated. Then the 
concentration of the sample was calculated according to their corresponding OD 
values.  
 
CALCULATION OF RESULTS 
 
Calibration graph : The standard curve was constructed by plotting concentration of 
each KIM-1 calibrator in ng/ml along the x-axis against the OD values of the 
corresponding calibrator along y-axis. 
 
  
KIM-1 values of samples : 
   The KIM-1 concentration of each sample was found by locating the point on the curve 
corresponding to the absorbance values for the samples and reading its corresponding 
concentration in ng/ml from the x-axis. 
 
ASSAY RANGE : 0.5ng/ml - 10ng/ml 
SENSITIVITY : 0.01ng/ml 
VALIDITY & STORAGE : 6 months when stored at 2-8°C and 12months at -20°C 
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    QUANTITATIVE ESTIMATION OF SERUM CREATININE 
            MODIFIED JAFFE’S REACTION, INITIAL RATE 
 
PRINCIPLE OF THE METHOD 
                 Creatinine reacts with picric acid in an alkaline medium to form an orange-
yellow color which is termed as Jaffe’s reaction. The initial rate method is introduced to 
improve the specificity of the test. The optical density of the orange-yellow color formed 
is directly proportional to the concentration of creatinine, which is measured 
photometrically at 500 to 520nm. 
 
COMPOSITION OF THE REAGENT 
 Reagent 1 - Picric Acid Reagent 
   Picric acid : 25.8 mmol/L 
 Reagent 2 - Sodium Hydroxide Reagent 
   Sodium hydroxide : 95 mmol/L 
 Creatinine standard 
   Creatinine standard : 2 mg/dl (0.166 mmol/L) 
 
 
 
 REAGENT PREPARATION 
    Equal volumes of Reagent 1 and Reagent 2 are mixed and wait for 15 minutes before 
use.  
 
STORAGE AND STABILITY 
                   Reagents 1, 2 and standard when unopened remain stable till the expiry date. 
The Working Reagent is stable for 21 days at 2-8°C. The absorbance of the reagent blank 
should be <0.3 at 505nm when read against distilled water. 
 
ASSAY PARAMETERS 
Wavelength (nm)        : 505 
Mode                           : fixed time 
Sample volume          : 100 μl 
Reagent volume         : 1000 μl 
Lag time                     : 20 sec 
Kinetic interval         : 60 sec 
No. of readings         : 1 
Reaction temperature    : 37°C 
Normal low              : 0.6 mg/dl 
Normal high             : 1.4 mg/dl 
Reaction direction       : increasing 
Linearity low               : 0 mg/dl 
Linearity high              : 25 mg/dl 
Absorbance limit (max)  : 0.3 
Standard concentration  : 2 mg/dl 
Blank with                  : water 
Units                           : mg/dl 
 
ASSAY PROCEDURE 
 
PIPETTE STANDARD TEST 
Working reagent 1000μl 1000μl 
Standard 100μl - 
Test - 100μl 
 
The test tubes were shaken to mix the contents and the initial absorbance was read within 
20 seconds of mixing and final absorbance at 80 seconds. 
 
 
CALCULATION  
The results are calculated as follows : 
ΔA = A2 - A1 
Creatinine concentration in mg/dl = ΔA of the test  × concentration of  
                                                           ΔA of standard     standard(mg/dl) 
 
LINEARITY 
                The assay is linear upto a value of 25mg/dl. For higher values the samples were 
diluted with normal saline and the assay repeated. Then the results were multiplied with 
the dilution factor.  
 
NORMAL VALUES 
For males   : 0.7 - 1.4 mg/dl 
For females : 0.6 - 1.2 mg/dl 
 
 
 
 
 
 
 
QUANTITATIVE DETERMINATION OF UREA BY UREASE 
METHOD ( GLUTAMATE DEHYDROGENASE - FIXED TIME) 
 
The method is used to determine urea in serum / plasma. 
METHODOLOGY 
It is a kinetic, enzymatic method.  
 
PRINCIPLE OF THE METHOD 
                            Urease  
Urea + 2H2O                                       2NH4+  + CO32- 
                                                               GLDH 
NH4+ + 2-Oxoglutarate + NADH                                L-glutamate + NAD+ + H2O 
                       The rate of change of absorbance at 340nm is directly proportional to the 
concentration of urea in serum. 
 
REAGENT COMPOSITION 
Tris buffer (pH 7.8) : 96 mmol/L 
ADP             :  0.6 mmol/L 
Urease           : 16000U/L 
GLDH           : 960 U/L 
NADH           : 0.25 mmol/L 
2-Oxoglutarate     : 9 mmol/L  
Urea standard : 50 mg/dl  
 
WORKING REAGENT PREPARATION & STABILITY 
Working reagent is prepared by mixing 4 parts of reagent R1 with one part of reagent R2.  
                 The working reagent (4R1 : 1R2) is stable for 30 days at 2-8°C, when 
protected from light and contamination. Fresh working solution is prepared before the 
assay is performed. 
 
STORAGE & STABILITY 
                 Reagent solutions R1 and R2 and standard are stable when unopened, till the 
expiry date when stored at 2-8°C. 
                Reagent deterioration may be detected when there is turbidity or when the 
reagent blank absorbance is <0.8 at 340nm. 
 
ASSAY PARAMETERS  
Mode                   : fixed time 
Wavelength              : 340 nm 
Sample volume           : 20 μl 
Reagent volume         : 1000 μl 
Lag time               : 20 seconds 
Kinetic interval          : 60 seconds 
No. of readings         : 1 
Reaction temperature     : 37°C 
Reaction direction       : decreasing  
Normal low            : 13 mg/dl 
Normal high            : 45 mg/dl 
Linearity low           : 0 mg/dl 
Linearity high           : 250 mg/dl 
Absorbance limit (min.)   : 0.8 
Blank with             : water  
Concentration of standard: 50 mg/dl           
Units                  : mg/dl 
 
ASSAY PROCEDURE 
PIPETTE STANDARD TEST 
Working reagent 1000 μl 1000 μl 
Standard 20 μl - 
Sample - 20 μl 
 
CALCULATION 
Urea concentration in mg/dl = Δ Absorbance of the test  × concentration of  
                                                  Δ Absorbance of standard     standard(mg/dl) 
 
 
REFERENCE VALUES 
In serum/plasma : 13 - 45 mg/dl 
 
LINEARITY 
The assay is linear upto 250 mg/dl. . For higher values the samples were diluted with 
normal saline and the assay repeated. Then the results were multiplied with the dilution 
factor.  
SENSITIVITY : 2.0 mg/dl 
 
INTERFERENCE: 
    Haemoglobin interferes upto 400 mg/dl, ascorbate upto 30 mg/dl, bilirubin upto 30 
mg/dl and triglycerides upto 2000 mg/dl do not interfere with the test. 
 
 
       
 
 
 
 
 
  
 
RESULTS & 
STATISTICS 
 
 
 
 
 
 
                      STATISTICAL ANALYSIS 
  
 
 Student’s t-test was employed for the statistical analysis of data. 
 The data were expressed in terms of mean and standard deviation. 
 ‘P’ value less than 0.05 was taken as the significant value. 
 Correlation between the measured parameters was assessed using Pearson’s 
correlation coefficient. 
 
 
                     
 
 
 
 
 
 
                         
      
                                 RESULTS  
 
              A total of 100 subjects were selected for the study. This included 50 patients 
with snake bite and 50 patients with sepsis. 
                    Levels of urinary KIM-1 was estimated on the day of admission within 24 
hours. Serum creatinine and blood urea were estimated on the day of admission and on 
the third day for all the samples. Those patients who developed AKI were considered as 
cases and those who did not develop AKI were considered as controls. The stage of AKI 
was interpreted using RIFLE criteria. 
                   The values obtained in snake bite and sepsis cases are presented in the master 
charts I and II respectively. 
 
Table 1 : 
 Shows comparison of  urinary levels of KIM-1 in cases and controls with snake bite.  
                   The mean value of  urinary KIM-1 in cases was 4.812 ng/ml and this was 
significantly higher than that of control group ( 0.544 ng/ml, ‘p’ < 0.001). 
Table 2 :  
Shows age matched urinary KIM-1 values between cases and controls with snake 
bite.  
                    There is no significant difference in urinary KIM-1 values in different age 
groups in different age groups among cases with ‘p’ value of 0.392 and among controls 
with ‘p’ value of 0.652.  
 
Table 3 : 
 Shows urinary KIM-1 values among males and females in cases and controls with 
snake bite. 
                      The mean level in males (0.54ng/ml) and  females (0.55ng/ml) among 
controls and males (5.81ng/ml) and females (2.9ng/ml) among cases was compared.  
There was significant difference in urinary KIM-1 values between males and females 
among cases with ‘p’ value of 0.001, whereas there was no significant gender related  
difference among control group (‘p’ – 0.906). 
 
Table 4 : 
Shows comparison of serum creatinine values on day 1 and day 3 among cases and 
controls with snake bite. 
                        There is no significant change in serum creatinine level on day 1 between 
cases (mean : 0.864mg/dl) and controls (mean : 0.808mg/dl) with a ‘p’ value of 0.3557. 
On day 3, serum creatinine is significantly elevated in cases (mean : 3.152mg/dl) than in 
controls (mean : 1.03mg/dl) with a ‘p’ value of < 0.001. 
 
Table 5 : 
Shows comparison of blood urea values on day1 and day 3 among cases and controls 
with snake bite. 
                        Blood urea is not significantly elevated on day 1 between cases (mean: 
33.64mg/dl) and controls (mean : 32.52mg/dl) with a ‘p’ value of 0.607. On day 3, blood 
urea is significantly elevated in cases (mean: 86.68mg/dl) than controls (mean: 
40.6mg/dl) with a ‘p’ value of < 0.001. 
 
Table 6 : 
Shows comparison of urinary KIM-1, serum creatinine and blood urea between 
cases and controls with snake bite on day 1. 
                      There was a significant rise in the levels of urinary KIM-1 among cases 
than controls with a ‘p’ value of < 0.001 on day 1. On the other hand there was no 
significant rise in levels of serum creatinine (‘p’ value 0.356) and blood urea (‘p’ value 
0.607) between cases and controls on day 1. 
 
Table 7 : 
Shows the Pearsons correlation coefficient of urinary KIM-1 with serum creatinine 
and blood urea on day 1 and day 3 among cases with snake bite. 
                      There was no significant correlation of urinary KIM-1 with serum 
creatinine and blood urea on day1. But on day 3, there was a significant positive 
correlation of urinary KIM-1 with serum creatinine and blood urea among cases with 
snake bite. 
Table 8 : 
 Shows comparison of urinary levels of KIM-1 in cases and controls with sepsis.  
                      The mean value of  urinary KIM-1 in cases was 4.544 ng/ml and this was 
significantly higher than that of control group ( 0.56 ng/ml, ‘p’ < 0.001). 
 
Table 9 :  
Shows age  matched urinary KIM-1 values between cases and controls with sepsis.  
                       There is no significant difference in urinary KIM-1 values in different age 
groups among cases with a ‘p’ value of 0.3 and among controls with a ‘p’ value of 0.754. 
 
Table 10 : 
 Shows urinary KIM-1 values among males and female groups in cases and controls 
with sepsis. 
                        The mean level in males (0.557ng/ml) and  females (0.564ng/ml) among 
controls and males (4.306ng/ml) and females (5.05ng/ml) among cases was compared.  
There was no significant difference in urinary KIM-1 values between males and females 
among cases with ‘p’ value of 0.944, and among control group (‘p’ value 0.449). 
 
Table 11 : 
Shows comparison of  serum creatinine values on day 1 and day 3 among cases and 
controls with sepsis. 
                         There is no significant change in serum creatinine level on day 1 between 
cases (mean : 1.072mg/dl) and controls (mean : 0.86mg/dl) with a ‘p’ value of 0.056. On 
day 3, serum creatinine is significantly elevated in cases (mean : 3.656mg/dl) than in 
controls (mean : 1.034mg/dl) with a ‘p’ value of < 0.001. 
 
Table 12 : 
Shows comparison of blood urea values on day 1 and day 3 among cases and 
controls with sepsis 
                            Blood urea is not significantly elevated on day 1 between cases (mean : 
33.44mg/dl) and controls (mean : 32 mg/dl) with a ‘p’ value of 0.667. On day 3, blood 
urea is elevated in cases (mean : 102.76mg/dl) than controls (mean : 38.52mg/dl) with a 
‘p’ value of < 0.001. 
 
Table 13 : 
Shows comparison of urinary KIM-1, serum creatinine and blood urea between 
cases and controls with sepsis on day 1. 
                           There was a significant rise in the levels of urinary KIM-1 among cases 
than controls with a ‘p’ value of < 0.001 on day 1. On the other hand there was no 
significant rise in levels of serum creatinine (‘p’ value 0.56) and blood urea (‘p’ value 
0.667) between cases and controls on day 1. 
 
Table 14 : 
Shows the Pearsons correlation coefficient of urinary KIM-1 with serum creatinine 
and blood urea on day 1 and day 3 among cases with sepsis.          
                There was no significant correlation of urinary KIM-1 with serum creatinine, 
however on day 3, there was a significant positive correlation of urinary KIM-1 with 
serum creatinine.  
                 There was a significant positive correlation of urinary KIM-1 with blood urea 
on day 1. A more significant positive correlation was observed on day 3 between urinary 
KIM-1 and blood urea among cases with sepsis. 
 
Table 15 :  
Shows the distribution of snake bite cases who developed AKI according to KDIGO 
staging of AKI and urinary KIM-1 levels.  
 
Table 16 : 
Shows ANOVA test which was applied to test the difference in mean KIM-1 levels 
among groups with different stages of AKI following snake bite. 
There was significant difference (‘p’<0.001) in urinary KIM-1 levels among groups with 
different stages of AKI. 
 
Table 17 : 
Shows the distribution of sepsis cases who developed AKI according to KDIGO 
staging of AKI and urinary KIM-1 levels.  
 
Table 18: 
Shows ANOVA test which was applied to test the difference in mean KIM-1 levels 
among groups with different stages of AKI following sepsis. 
There was significant difference (‘p’<0.001) in urinary KIM-1 levels among groups with 
different stages of AKI. 
 
 
Figure 4 :  
                   Bar diagram showing comparison of urinary KIM-1 values among cases and 
controls with snake bite. 
Figure 5: 
                Bar diagram showing urinary KIM-1 in different age groups among cases and 
controls with snake bite. 
 
Figure 6 : 
              Bar diagram showing comparison of urinary KIM-1 in males and females among 
cases and controls with snake bite. 
Figure 7 : 
              Bar diagram showing comparison of serum creatinine on day 1 and day 3 among 
cases and controls with snake bite. 
Figure 8 : 
              Bar diagram showing comparison of blood urea on day 1 and day 3 among cases 
and controls with snke bite. 
Figure 9 : 
              Bar diagram showing comparison of urinary KIM-1 among cases and controls 
with sepsis. 
Figure 10 : 
               Bar diagram showing urinary KIM-1 in different age groups among cases and 
controls with sepsis. 
Figure 11 : 
              Bar diagram showing urinary KIM-1 in males and females among cases and 
controls with sepsis. 
Figure 12 : 
              Bar diagram showing comparison of serum creatinine on day 1 and day 3 among 
cases and controls with sepsis. 
Figure 13 : 
              Bar diagram showing comparison of blood urea on day 1 and day 3 among cases 
and controls with sepsis. 
Figure 14 : 
             Box plot showing comparison of urinary KIM-1 among 3 stages of AKI in snake 
bite cases. 
Figure 15 : 
             Box plot showing comparison of urinary KIM-1 among 3 stages of AKI in sepsis 
cases. 
 
 
 
 
 
 
 
 
 
 
TABLE 1 - Comparison of urinary  KIM-1 among cases and 
controls with snake bite 
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(ng/ml) 
Control Cases 
Range  0.1 - 0.9 1.2 -  8.9 
Mean  0.544 4.812 
Standard deviation 0.24 2.53 
‘p’ value <0.001 
Significant 
TABLE 2 - Comparison of urinary KIM-1 in different age groups 
among cases and controls with snake bite 
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Age group  Controls  Cases  
Mean  S.D. Mean  S.D. 
<40 years 0.523 0.283 4.44 2.438 
≥40 years 0.567 0.187 5.37 2.697 
‘p’ value 0.652 
Not significant 
0.392 
Not significant 
TABLE 3 - Comparison of urinary KIM-1 among males and 
females in cases and controls with snake bite 
 
Sex  Controls Cases  
Mean  S.D. Mean  S.D. 
Males  0.538 0.272 5.81 2.37 
Females 0.55 0.206 2.9 1.238 
‘p’ value 0.906 
Not significant 
0.001 
Significant 
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TABLE 4 - Comparison of serum creatinine on day 1 and 
day 3 among cases and controls with snake bite 
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Creatinine values 
on 
Controls Cases  ‘p’ value 
Mean  S.D. Mean  S.D. 
Day 1 0.808 0.191 0.864 0.175 0.3557 
Not significant 
Day 3 1.03 0.232 3.152 2.24 0.0001 
Significant  
TABLE 5 - Comparison of blood urea on day 1 and day 3 
among cases and controls with snake bite 
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Urea values on Controls Cases  ‘p’ value 
Mean  S.D. Mean  S.D. 
Day 1 32.52 6.66 33.64 7.28 0.607 
Not significant 
Day 3 40.06 9.87 86.68 40.40 <0.001 
Significant  
  
 
 
TABLE 6 - Comparison of urinary KIM-1 with serum 
creatinine and blood urea on day 1 in patients with snake 
bite 
 
Day -1 Mean S.D. ‘p’ value 
KIM-1 Cases 
Controls 
4.812 
0.544 
2.53 
0.24 
<0.001 
Significant 
Serum 
creatinine 
Cases  
Controls 
0.864 
0.808 
0.175 
0.191 
0.356 
Not significant 
Blood urea  Cases 
Controls  
33.64 
32.52 
7.28 
6.66 
0.607 
Not significant 
 
 
 
 
 
  
 
 
TABLE 7 - Pearson’s correlation coefficient between 
urinary KIM-1, serum creatinine and blood urea in patients 
with snake bite 
 
 
Correlation between Correlation 
coefficient 
Correlation  
KIM-1 and creatinine on day 1 0.094 Not correlated 
KIM-1 and creatinine on day 3 0.882 Correlated  
KIM-1 and urea on day 1 0.380 Not correlated 
KIM-1 and urea on day 3 0.864  Correlated  
 
 
 
 
TABLE 8 - Comparison of urinary  KIM-1 among cases and 
control with sepsis 
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Range  0.2 - 0.9 1.2 - 7.9 
Mean  0.56 4.544 
Standard deviation 0.216 2.268 
‘p’ value <0.001 
Significant 
TABLE 9 - Comparison of urinary KIM-1 in different age 
groups among cases and controls with sepsis 
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Age group  Controls  Cases  
Mean  S.D. Mean  S.D. 
<40 years 0.538 0.256 4.042 2.4217 
≥40 years 0.571 0.202 5.008 2.1057 
‘p’ value 0.754 
Not significant 
0.30 
Not significant 
TABLE 10 - Comparison of urinary KIM-1 among males 
and females in cases and controls with sepsis 
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Sex  Controls Cases  
Mean  S.D. Mean  S.D. 
Males  0.557 0.199 4.306 2.33 
Females 0.564 0.246 5.05 2.18 
‘p’ value 0.944 
Not significant 
0.449 
Not significant 
TABLE 11 - Comparison of serum creatinine in cases and 
controls with sepsis 
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Creatinine values 
on 
Controls Cases  ‘p’ value 
Mean  S.D. Mean  S.D. 
Day 1 0.86 0.191 1.072 0.499 0.056 
Not significant 
Day 3 1.034 0.195 3.656 2.585 <0.001 
Significant 
TABLE 12 - Comparison of serum urea in cases and 
controls with sepsis 
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Urea values on Controls Cases  ‘p’ value 
Mean  S.D. Mean  S.D. 
Day 1 32 7.836 36.44 8.347 0.0667 
Not significant 
Day 3 38.52 6.982 102.76 55.074 <0.001 
Significant 
           
 
TABLE 13 - Comparison of urinary KIM-1 with serum 
creatinine and blood urea on day 1 in patients with sepsis 
 
Day -1 Mean S.D. ‘p’ value 
KIM-1 Cases 
Controls 
4.544 
0.56 
2.268 
0.216 
<0.001 
Significant 
Serum 
creatinine 
Cases  
Controls 
1.072 
0.86 
0.499 
0.191 
0.056 
Not significant 
Blood urea  Cases 
Controls  
36.44 
32 
8.347 
7.836 
0.0667 
Not significant 
 
 
 
 
 
 
  
TABLE 14 - Pearson’s correlation coefficient between 
urinary KIM-1, serum creatinine and blood urea in patients 
with sepsis 
 
 
Correlation between Correlation 
coefficient 
Correlation  
KIM-1 and creatinine on day 1 0.439 Not correlated 
KIM-1 and creatinine on day 3 0.888 Correlated  
KIM-1 and urea on day 1 0.688 Correlated  
KIM-1 and urea on day 3 0.871 Correlated  
 
 
 
 
 
                                                      
 
 
Table 15 : Distribution of snake bite cases who developed AKI 
according to KDIGO staging of AKI and urinary KIM-1 levels.  
 
 
 
Stages of 
AKI 
N Mean 
KIM-1 
level 
Standard 
deviation 
Standard 
error 
Stage 1 8 2.025 0.656 0.232 
Stage 2 8 4.2875 0.710 0.251 
Stage 3 9 7.755 0.792 0.264 
Table 16 : ANOVA test to test the difference in mean KIM-1 levels 
among groups with different stages of AKI following snake bite. 
P value <0.001 
F statistic 135.356 
Degree of freedom 2 
 
                                              Figure 14 : 
 
  
Table 17 :Distribution of sepsis cases who developed AKI 
according to KDIGO staging of AKI and urinary KIM-1 levels.  
 
 
 
 
Stages of 
AKI 
N Mean 
KIM-1 
level 
Standard 
deviation 
Standard 
error 
Stage 1 8 1.800 0.374 0.132 
Stage 2 8 4.475 0.785 0.277 
Stage 3 9 7.0444 0.461 0.154 
Table 18: ANOVA test to test the difference in mean KIM-1 levels 
among groups with different stages of AKI following sepsis. 
P value <0.001 
F statistic 183.214 
Degree of freedom 2 
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    DISCUSSION 
 
 
 
 
 
 
 
                                         DISCUSSION 
            
      Acute Kidney Injury is a common cause of morbidity and mortality 
among hospitalized patients. Hence, sensitive biological markers for renal tubular injury 
are needed in order to detect early kidney injury and facilitate timely introduction of 
treatment. Till date, the standard test which is done to detect AKI is serum creatinine. 
                 However, serum creatinine has shown numerous limitations as a marker 
to detect AKI, which affects its early diagnosis as well as prognosis. 
      Serum creatinine will be detected in serum only after 50% of renal cell death 
has occurred. It does not accurately depict kidney function until a steady state has been 
reached.  
Serum creatinine levels are relatively insensitive to small changes in GFR and may 
lag behind changes in GFR by several days. Damage to renal tubules alone is not 
sufficient to result in a change in serum creatinine. Hence it does not allow for early 
detection of acute renal injury.  
  The change in serum creatinine does not discriminate the time and type of renal 
insult or the site and extent of glomerular or tubular injury.  
 
To deal with these issues, better biological markers of AKI are needed, which 
should meet several requirements such as, 
 Allow for early detection of kidney injury 
 Identify the severity of kidney injury 
 Provide a criteria for risk stratification and identify those patients who are 
at risk for AKI 
 Guide timing of treatment 
 Reflect improvement and deterioration of kidney injury. 
 
               This study evaluates the use of urinary Kidney Injury Molecule-1 (KIM-1) as a 
biomarker of AKI and for early diagnosis of AKI when compared to serum creatinine and 
blood urea.  
              In the present study, among patients who were admitted for snake bite, the mean 
value of  urinary KIM-1 in those who developed AKI (cases) was significantly higher 
than that among those who did not develop AKI (control group).  
                Likewise, among patients who had sepsis, the mean value of  urinary KIM-1 in 
cases was found to be significantly higher than that of control group. 
               Urinary KIM-1 was compared among age groups of <40 years and ≥40 years. 
Among patients with snake bite as well as sepsis, it was found that there was no 
significant difference in urinary KIM-1 values in different age groups among cases and 
controls. This shows that age doesn’t have any influence on urinary KIM-1 values. 
                     Further, when urinary KIM-1 was estimated and compared between males 
and females, among snake bite cases, it was found that urinary KIM-1 values are 
significantly high among males when compared to females, whereas there was no 
significant difference between males and females among controls. 
               Among patients with sepsis, there was no significant difference in urinary KIM-
1 values between males and females among cases, as well as between control males and 
control females. This implies that gender does not influence the values of urinary KIM-1 
in patients with sepsis. 
              In this study, when serum creatinine was compared between cases and controls 
on day1. Both among patients with snake bite and sepsis it was found that there was no 
significant difference. On day 3, among patients with snake envenomation, serum 
creatinine is significantly elevated in cases than in controls, as also among patients with 
sepsis. 
          Similarly blood urea was compared among cases and controls on day 1. In patients 
with snake bite as well as sepsis, blood urea was not significantly elevated on day 1 
between cases and controls. Whereas, on day 3, blood urea is elevated in both snake bite 
as well as sepsis cases than among controls.  
       This study shows that rise in serum creatinine and blood urea level is observed 
only on the 3rd day of nephrotoxic insult who developed acute kidney injury. 
       On day 1, when urinary KIM-1 was compared with serum creatinine and 
blood urea, it was found that among patients with snake bite, there was a significant rise 
in the levels of urinary KIM-1 among cases than controls with a ‘p’ value of < 0.001. But, 
there was no significant rise in levels of serum creatinine (‘p’ value 0.356) and blood urea 
(‘p’ value 0.607) between cases and controls on day 1.  
                  Also among patients with sepsis, there was a significant rise in the levels of 
urinary KIM-1 among cases than controls with a ‘p’ value of < 0.001 on day 1. But there 
was no significant rise in levels of serum creatinine (‘p’ value 0.56) and blood urea (‘p’ 
value 0.667) between cases and controls on day 1. 
     This shows that urinary KIM-1 levels rise much earlier than the traditional 
biomarkers such as serum creatinine and blood urea. 
      In the present study, the correlation of urinary KIM-1 with traditional markers, 
serum creatinine and blood urea on day 1 and day 3 was determined using Pearson’s 
correlation. It was found that in patients who developed AKI following snake 
envenomation, there was no significant correlation noticed between rise in urinary KIM-1 
and serum creatinine as well as blood urea on the day of admission. Progressive kidney 
damage leading to rise in serum creatinine shows a significant positive correlation 
between urinary KIM-1 and serum creatinine, blood urea on day 3. 
      Among patients with sepsis who developed AKI, it was found that there was 
no significant correlation of urinary KIM-1 with serum creatinine on day1. But on day 3, 
there was a significant positive correlation. On day 1, although it was found that there 
was a significant positive correlation between urinary KIM-1 and blood urea, on day 3 
urinary KIM-1 was more significantly correlated with blood urea. 
                     The cases of snake bite and sepsis who developed AKI were categorized 
into three groups, stage 1, 2 and 3, on the basis of KDIGO staging for AKI. The 
descriptive statistics of urinary KIM-1 for each stage of AKI was determined. Further, 
ANOVA test was applied to test for the difference between the means of the three groups. 
                    It was found that among snake bite cases, there was a significant difference 
between the mean of stage 1 AKI (2.025ng/ml). stage 2 AKI (4.287ng/ml) and stage 3 
AKI (7.755ng/ml), with a ‘p’ value of <0.001. Likewise, among sepsis cases, there was a 
significant difference between the mean of stage 1 AKI (1.8ng/ml). stage 2 AKI 
(4.475ng/ml) and stage 3 AKI (7.044ng/ml), with a ‘p’ value of <0.001. 
                  Thus in both snake bite and sepsis cases it was found that the levels of urinary 
KIM-1 increases with severity of AKI. 
 
                                All these findings show that urinary KIM-1 is sensitive to minor 
disturbances  in the renal function, specific and a noninvasive method for the early 
diagnosis and evaluation of acute kidney injury when compared with traditional markers 
such as serum creatinine and blood urea. 61 Urinary KIM-1 levels correlate with the 
degree of severity of tubular injury. In the setting of ischemic acute tubular necrosis, 
KIM-1 is an efficient marker to diagnose within 24 hours of kidney injury.62,63 
                       In response to an acute insult to the renal tubules, the proximal tubular 
epithelial cells undergo dedifferentiation. Kidney Injury Molecule-1 expression is 
markedly upregulated in these dedifferentiated cells. Epithelial cellular stress leads to 
activation of Mitogen Activated Protein Kinase (MAPK) pathway, following which the 
heavily glycosylated KIM-1 ectodomain is shed from the cellular surface into the tubular 
lumen by the action of Matrix Metalloproteinases (MMPs). This leads to release of a 
90kDa soluble form which is excreted in urine. 
                            
             The characteristic features of KIM-1 which make it an ideal biomarker include: 
 It is specifically expressed only in the injured proximal tubular cells of kidney and is 
virtually absent in normal healthy kidneys. It persists till the injured cells are completely 
recovered. 
 The rapidly cleaved ectodomain which sheds into the tubular lumen makes it 
detectable in urine. Urinary KIM-1 correlates with tissue KIM-1 as well as the severity of 
kidney damage. 
 This qualifies urinary KIM-1 as a non-invasive, sensitive, rapid and reproducible  
method to evaluate renal injury.64,65 
 Urinary KIM-1 serves as a prognostic indicator of rate of decline of renal function, 
irrespective of renal pathology. 
 The detection of KIM-1 in urine within 12 hours following ischemia or toxic injury 
makes it an early diagnostic indicator compared to the traditional biomarkers such as 
blood urea nitrogen and serum creatinine.66 
 The appearance of KIM-1 before the detection of lethal injury to proximal tubular 
epithelial cells allows for timely reversal and treatment of kidney injury.53 
 Since  KIM-1 is found to be stable in urine even after repeat freeze-thaw cycles, a 
methodological advantage is that no stabilizing buffer or protease inhibitor is required to 
prevent its degradation  while collecting urine samples.20,67  
 KIM-1 detected by ELISA is associated with minimal interference by other urinary 
components of the diseased patient and is unaffected by physic-chemical changes in 
urine.56   
 KIM-1 is also a tool to evaluate renal injury in biopsy specimen using 
immunohistochemical methods, and its upregulation has been correlated with 
inflammation and tubule-interstitial fibrosis. 
 The behavior of KIM-1 in human mirrors as in animals. Thus it is a ‘true 
translational biomarker’ which can be used in drug development, evaluation of toxicity of 
new candidate therapeutics and safety monitoring of kidneys.3,31 The Food and Drug 
Administration of United States (FDA) and European Medicines Agency (EMEA) has 
qualified KIM-1 for the preclinical assessment of nephrotoxicity  to improve the 
monitoring of kidney safety.68    
            The utility of KIM-1 has also been found in several other conditions such as 
1) Chronic kidney disease 
2) Diabetic glomerulopathy .9  
3) Acute or chronic renal transplant dysfunction.61 
4) Biomarker for renal cell carcinoma20 
5) Kidney injury in chidren undergoing cardiac surgery3 
6) IgA nephropathy associated with tubule-interstitial injury69 
 
 
  
 
 
 
 
CONCLUSION 
 
 
                                    CONCLUSION  
 
                This study on patients with snake envenomation and sepsis shows that urinary 
Kidney Injury Molecule-1 is a promising early predictive bio-marker of acute kidney 
injury when compared to the traditional biomarkers such as serum creatinine and blood 
urea.   
                This novel bio- marker might facilitate earlier diagnosis of  acute kidney injury 
and management decision including administration of specific preventive and therapeutic 
strategies, potentially resulting in fewer morbidity and mortality. 
 
    
 
 
 
 
 
  
 
                              LIMITATIONS 
 
                   This study had the following limitations : 
1. The sample size was small. 
2. Urinary KIM-1 was analyzed only on the day 1 of admission. It is not clear if 
KIM-1 level in the urine shows fluctuations with time. 
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STUDY OF URINARY LEVEL OF KIDNEY INJURY MOLECULE-1 
(KIM-1) IN ACUTE KIDNEY INJURY –PROFORMA 
 
NAME OF THE PATIENT : 
 
AGE/SEX              : 
 
OCCUPATION  : 
 
ADDRESS   : 
 
COMPLAINTS  : 
 
PAST HISTORY  : 
 
PERSONAL HISTORY : 
 
FAMILY HISTORY  : 
 
DRUG HISTORY  : 
 
GENERAL EXAMINATION:          
Ht:                Wt:            BMI:               BP:                 PR: 
 
 SYSTEMIC EXAMINATION:      
                                            CVS:                                                   RS:                                                           
                                            ABD:                                                  CNS:                                                                                     
 
INVESTIGATIONS : 
 
1.BLOOD UREA: 
 
2.SERUM CREATININE 
 
3. URINARY KIDNEY INJURY MOLECULE-1: 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
                                                            CONSENT FORM 
 
 
Dr .NEETHU VARGHESE post graduate student in the Department of Biochemistry, 
Thanjavur medical college, Thanjavur is doing a dissertation on Study of Urinary level of 
Kidney Injury Molecule-1 (KIM-1) in Acute Kidney Injury. The procedure has been 
explained to me clearly. I understand that there are no risks involved in the above 
procedures. I hereby give my consent to participate in this study. The data obtained here 
may be used for research and publication. 
 
Signature : 
 
Name: 
 
Place:  
 
 
 
                                    MASTER CHART  I  -  SNAKE  BITE  CONTROLS 
S.No AGE 
(years) 
SEX Type of 
Snake 
Blood 
Pressure 
(mmHg) 
Pulse 
Rate 
(per 
minute) 
Clotting 
time 
(minutes) 
Urinary 
KIM-1 
(ng/ml) 
Serum     
creatinine    
(mg/dl) 
Blood urea 
(mg/dl) 
Stage of 
AKI 
Day 1 Day 3 Day 1 Day 3 
1 75 M Viper 110/70 76 18 0.4 1.1 1 32 38 No AKI 
2 43 M Viper 112/68 82 >20 0.6 0.8 1.1 36 45 No AKI 
3 34 F Unknown 120/80 73 6 0.6 0.6 0.7 29 24 No AKI 
4 20 M Unknown 120/80 72 10 0.2 0.7 1 35 40 No AKI 
5 45 F Unknown 110/70 70 16 0.7 0.9 1.3 28 64 No AKI 
6 40 M Unknown 120/70 79 7 0.9 0.6 0.8 29 32 No AKI 
7 65 F Unknown 130/80 80 9 0.5 1 1.4 30 45 No AKI 
8 18 F Viper 110/68 83 15 0.2 0.6 0.8 38 68 No AKI 
9 19 M Viper 110/80 71 8 0.9 0.6 0.8 32 40 No AKI 
10 18 M Unknown 120/80 74 6 0.4 0.6 0.7 20 38 No AKI 
11 21 M Unknown 110/70 74 7 0.8 0.6 0.7 21 40 No AKI 
12 55 M Unknown 120/80 76 10 0.4 1.2 1.3 44 47 No AKI 
13 73 M Unknown 120/70 78 12 0.7 1 1.2 34 36 No AKI 
14 23 F Unknown 120/80 70 9 0.1 0.8 1 24 32 No AKI 
15 62 F Unknown 110/68 76 18 0.7 0.9 1.1 36 42 No AKI 
16 35 F Unknown 108/70 82 10 0.6 0.7 0.8 28 22 No AKI 
17 22 M Viper  120/70 80 9 0.9 1.1 1.5 40 38 No AKI 
18 43 F Viper 110/80 76 12 0.6 0.7 1.1 29 43 No AKI 
19 41 M Unknown 110/70 78 8 0.3 0.9 1.1 30 35 No AKI 
20 22 F Unknown 110/80 75 15 0.5 0.8 1.1 36 46 No AKI 
21 18 F Unknown  110/70 76 19 0.8 0.6 0.8 33 46 No AKI 
22 42 F Unknown 110/70 76 5 0.7 0.9 1.25 48 43 No AKI 
23 32 M Unknown 112/78 84 18 0.2 0.7 0.9 30 35 No AKI 
24 54 M Viper 130/70 77 15 0.3 1.1 1.3 42 38 No AKI 
25 37 F Unknown  120/70 84 14 0.6 0.7 1 29 38 No AKI 
                                                             
                                                       
                                                               MASTER  CHART  I  -  SNAKE  BITE  CASES 
S.No AGE 
(years) 
SEX Type of 
Snake 
Blood 
Pressure 
(mmHg) 
Pulse 
Rate 
(per 
minute) 
Clotting 
time 
(minutes) 
Urinary 
KIM-1 
(ng/ml) 
Serum     
creatinine    
(mg/dl) 
Blood urea 
(mg/dl) 
Stage 
of AKI 
Day 1 Day 3 Day 1 Day 3 
1 22 F Unknown  120/80 80 7 1.2 0.6 0.9 26 42 1 
2 60 F Unknown 108/72 90 17 3.5 0.9 1.9 34 80 2 
3 24 M Unknown 102/72 82 >20 7.2 0.7 3.2 40 154 3 
4 48 M Viper 110/70 74 >20 7.5 0.8 6.4 46 160 3 
5 45 F Viper 110/80 75 10 4.5 0.8 2.1 28 66 2 
6 40 M Unknown 110/70 75 >20 8.2 0.8 7.4 29 112 3 
7 20 F Viper  120/70 76 13 1.8 0.9 1.35 38 82 1 
8 39 M Unknown 110/70 72 11 4.3 1.2 2.4 27 54 2 
9 40 F Viper 120/70 70 9 3.7 1.2 2.4 46 60 2 
10 20 F Unknown 110/64 90 >20 3.9 0.9 2 38 78 2 
11 37 M Unknown 106/66 94 >20 6.8 0.8 6.6 40 103 3 
12 33 M Viper 120/80 80 6 1.5 0.8 1.2 32 44 1 
13 45 M Viper 110/70 72 16 5.5 0.9 2.5 24 74 2 
14 24 M Unknown 110/80 78 15 6.7 0.8 3.1 42 150 3 
15 49 M Unknown 110/70 76 >20 8.2 0.9 6.2 44 154 3 
16 44 F Unknown 120/80 74 15 2.4 0.8 1.4 27 66 1 
17 63 F Unknown 120/80 72 7 1.3 1.1 1.65 34 44 1 
18 38 M Unknown 120/70 73 >20 8.7 0.9 7.5 30 130 3 
19 38 M Unknown 120/84 82 7 5.1 1.2 2.4 30 70 2 
20 20 M Unknown 120/80 80 6 2.8 0.7 1.05 34 48 1 
21 16 M Unknown 110/80 78 10 2.4 0.6 0.9 20 39 1 
22 22 F Viper 112/70 90 15 3.8 0.8 2.1 37 76 2 
23 35 M Viper 120/80 78 12 7.6 0.7 6.6 36 104 3 
24 22 M Unknown 110/80 72 6 2.8 0.7 1.05 22 39 1 
25 45 M Viper  140/90 96 19 8.9 1.1 4.5 37 138 3 
                                               MASTER  CHART  II  -  SEPSIS  CONTROLS  
S. No Age 
(years) 
Sex  Septic foci Blood 
pressure 
(mmHg) 
Pulse 
rate  
(/min) 
Temp
eratur
e (°F) 
Urinary 
KIM-1 
(ng/ml) 
Serum creatinine 
(mg/dl) 
Blood urea 
(mg/dl) 
Stage of 
AKI 
Day 1 Day 3 Day 1 Day 3 
1 88 M Pyelonephritis 130/80 85 100.5 0.7 0.8 1 38 45 No AKI 
2 87 M Pneumonitis 130/80 83 101.2 0.9 0.6 0.7 34 42 No AKI 
3 24 M Encephalitis 110/70 76 100.6 0.3 0.6 0.8 26 32 No AKI 
4 55 M Pyelonephritis 110/60 96 101 0.5 1 1.2 40 45 No AKI 
5 27 F Puerperal sepsis 100/68 94 95.9 0.6 1 1.3 44 48 No AKI 
6 21 F Meningitis 110/80 76 101 0.7 0.6 0.9 22 30 No AKI 
7 68 M Pneumonitis 110/60 84 96.3 0.5 0.9 1.1 19 45 No AKI 
8 45 F Appendicitis 120/70 76 96.2 0.6 0.8 0.9 26 28 No AKI 
9 42 M Pneumonitis 140/90 112 101 0.7 0.9 1.3 32 40 No AKI 
10 80 M Pneumonitis 110/80 78 100.7 0.8 0.7 1 32 40 No AKI 
11 85 M Pneumonitis 140/90 112 100.5 0.7 0.6 0.85 36 40 No AKI 
12 52 M Puerperal sepsis 100/60 98 100.4 0.3 0.8 1 40 50 No AKI 
13 35 M Puerperal sepsis 100/60 96 100.5 0.3 1.1 1.2 46 40 No AKI 
14 40 F Pyelonephritis 100/58 106 100.9 0.9 0.9 1.1 38 40 No AKI 
15 40 M Pneumonitis 90/60 112 100.7 0.6 0.8 1.1 21 30 No AKI 
16 44 F Pyelonephritis 100/60 108 101.1 0.3 0.9 1.1 26 32 No AKI 
17 23 F Meningitis 120/80 76 101.2 0.2 0.7 0.9 24 28 No AKI 
18 42 F Appendicitis 110/70 74 100.6 0.4 0.9 0.8 26 28 No AKI 
19 40 M Encephalitis 120/70 72 101.2 0.6 1.1 1.2 46 50 No AKI 
20 66 M Pancreatitis 100/60 86 96.3 0.6 1.1 1.2 30 46 No AKI 
21 52 M Meningitis 100/62 90 96.1 0.3 1.1 1.2 30 35 No AKI 
22 38 F Pyelonephritis 96/60 110 101.3 0.5 1.1 1.4 36 40 No AKI 
23 23 F Puerperal sepsis 100/70 106 101.4 0.9 1.2 1.1 36 40 No AKI 
24 32 F Puerperal sepsis 96/60 79 96.4 0.8 0.7 0.8 28 34 No AKI 
25 43 F Puerperal sepsis 100/70 92 96.4 0.3 0.6 0.7 24 35 No AKI 
                                                              MASTER  CHART  II  -  SEPSIS  CASES 
S. No. Age  Sex  Septic foci Blood 
pressure  
(mmHg) 
Pulse 
rate 
(/min) 
Temper
ature 
(°F) 
Urinary 
KIM-1 
(mg/dl) 
Serum creatinine 
(mg/dl) 
Blood urea  
(mg/dl) 
Stages 
of AKI 
Day 1 Day 3 Day 1 Day 3 
1 65 M Pancreatitis 100/60 92 100.7 7.5 0.9 8.6 42 187 3 
2 50 M Meningitis 100/64 94 100.5 6.8 0.9 6.1 42 167 3 
3 38 M Pancreatitis 120/70 75 96.4 3.7 0.6 1.2 29 62 2 
4 25 F Puerperal sepsis 100/70 91 96.2 7.2 0.8 6.5 36 169 3 
5 41 F Pyelonephritis 96/60 102 96 6.5 0.9 3.3 39 153 3 
6 28 F Puerperal sepsis  100/60 96 101.3 1.9 0.8 1.3 40 42 1 
7 32 F Puerperal sepsis 108/70 87 101.1 2.2 0.9 1.4 26 44 1 
8 38 M Encephalitis 130/80 110 96.1 1.6 1.1 1.8 41 80 1 
9 21 F Puerperal sepsis 110/70 96 100.4 5.4 1.2 3.1 41 148 2 
10 63 M Pneumonitis 100/70 110 96.2 6.8 0.8 8.4 40 180 3 
11 25 M Encephalitis 110/70 82 100.4 1.8 0.9 1.6 30 48 1 
12 35 M Pancreatitis 110/70 84 96.5 3.3 0.7 2 30 60 2 
13 63 M Puerperal sepsis 100/60 76 96.3 6.6 0.9 6.4 34 170 3 
14 53 M Pyelonephritis 110/70 78 96.1 3.8 1.2 3.3 38 112 2 
15 65 M Pnemonitis 130/90 84 100.4 1.2 0.8 1.4 20 40 1 
16 40 M Pneumonitis 120/80 70 101.5 5.1 0.8 2.2 32 60 2 
17 22 F Puerperal sepsis 110/60 84 101.4 4.8 1.1 3.2 40 150 2 
18 25 F Puerperal sepsis 100/70 88 96.4 7.9 2.4 7.5 60 120 3 
19 53 M Pyelonephritis 100/60 92 101 2.2 1 1.3 28 35 1 
20 25 M Meningitis 100/62 98 101.3 1.4 0.7 0.9 24 40 1 
21 45 M Pyelonephritis 100/70 95 96.4 6.8 1.4 6.4 42 160 3 
22 67 F Puerperal sepsis 96/60 85 101 4.5 1.2 2.7 34 67 2 
23 54 M Pyelonephritis 100/70 88 101.3 5.2 1.1 2.5 38 73 2 
24 37 M Meningitis 110/60 78 101 7.3 2.8 7.2 49 154 3 
25 54 M Pyelonephritis 100/62 91 101.3 2.1 0.9 1.1 36 48 1 
 
